TW201742857A - Amide derivatives, preparation process thereof and use thereof in medicine - Google Patents

Abstract

Provided are amide derivatives, a preparation process thereof and a use thereof in medicine. More specifically, provided are amide derivatives represented by the general formula (I) or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and the use thereof as a therapeutic agent, in particular as a glucagon receptor antagonist.

Description

Guanidine derivatives, preparation methods thereof, pharmaceutical compositions thereof and their use in medicine

The present invention relates to a novel guanamine derivative, a process for its preparation and a pharmaceutical composition containing the same and its use as a therapeutic agent, in particular as a GCGR antagonist.

Glucagon is a linear polypeptide consisting of 29 amino acids secreted by islet alpha cells with a molecular weight of 3485; a concentration of 50-100 ng/L in serum and a half-life of 5-10 minutes in plasma. Glucagon specifically binds to the type B G-protein coupled receptor (glucagon receptor, GCGR) on the surface of target cells such as liver and kidney, and initiates a downstream signal transduction pathway to exert physiological effects. Contrary to the action of insulin, it is a hormone that promotes catabolism, and has a strong promotion of glycogenolysis and gluconeogenesis, resulting in a marked increase in blood sugar. A 1 mol/L hormone rapidly decomposes 3 x 10 ⁶ mol/L glucose from glycogen (Johnson et al., J. Biol. Chem. 1972, 247, 3229-3235).

The glycoside receptor is located on the cell surface and has G-protein coupled receptors with seven transmembrane sequences, mainly distributed in the liver, and also distributed in the kidney, heart, muscle, and the like.

The main target organ for glycosidic action is the liver. When bound to the receptor, it interacts with the guanine nucleotide to regulate the protein Gs, causing the release of the A subunit of Gs to initiate adenylate cyclase, which catalyzes the conversion of ATP to cAMP to exert its biological effects. Pharmacological doses of glycoside can increase cAMP content in cardiomyocytes and increase myocardial contraction. A glycemic receptor antagonist competes with the glycoside for the receptor, thereby blocking its action.

Diabetes is a disease that is highly expressed by plasma glucose. Uncontrolled hyperglycemia is associated with an increased risk of microvascular and macrovascular disease, including kidney disease, retinopathy, hypertension, stroke, and heart disease. The control of glucose homeostasis is the primary method of treating diabetes. It has been shown in healthy animals and animal models of type I and type II diabetes that the removal of circulating glyceins with selective and specific antibodies results in a decrease in blood glucose levels. Thus a potential treatment for diabetes and other diseases involving abnormal blood glucose is that the glycoside receptor antagonist blocks the glycemic receptor to increase the insulin response, to reduce the rate of gluconeogenesis and/or to reduce hepatic glucose in the patient. The output rate is used to lower plasma glucose levels.

A series of literatures on GCGR antagonists have been published, including WO2008042223, WO2010098994A1, WO2015066252, WO2012009226A1, WO2012009226A1, etc., and not all compounds that are GCGR antagonists have properties that are useful therapeutic agents. Some of these properties include high affinity for the glycemic receptor, duration of receptor activation, oral bioavailability and stability (eg, ability to formulate or crystallize, shelf life). Such properties can lead to improvements in safety, tolerability, effectiveness, therapeutic index, patient compliance, cost effectiveness, ease of preparation, and the like. Surprisingly, it has been found that the specific stereochemistry and functional groups of the compounds of the invention exhibit one or more of these desirable properties, including significantly improved receptor binding properties, oral bioavailability, and/or other enhancements for therapeutic use. An advantageous feature of suitability.

The GCGR antagonist drugs currently under investigation include: PF-06291874 (Pfizer) and LGD-6972 (Ligand) in clinical phase II, while Merck has developed MK-3577, and 3-(4-) is disclosed in WO2015066252. ((1R,2S)-1-(5-chloro-7-fluoro-1H-indol-3-yl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzene Mercapto)propionic acid (FORM1), which is an analog of MK-3577, relates to the structure of a specific compound as follows:

In order to overcome the deficiencies of the prior art, it is an object of the present invention to provide a novel class of guanamine derivatives of the formula (I), as well as tautomers, enantiomers, diastereomers thereof, The compound and the pharmaceutically acceptable salt, as well as the metabolite and the metabolic precursor or the prodrug, have a large structural difference with the compound specifically disclosed in the prior art, and exhibit excellent anti-diabetic effects and effects. The structure of formula (I) is as follows:

among them:

L is selected from -C(O)NH- or -NH-C(O)-;

A ₁ , A ₂ , A ₃ , A ₄ and A ₅ are each independently selected from CH, C or N, provided that A ₁ , A ₂ , A ₃ , A ₄ and A ₅ and the carbon atom to which they are attached The number of N in the ring is 0 to 2;

R ^{1 is} selected from an alkyl group or a cycloalkyl group, wherein the alkyl group or cycloalkyl group is further optionally further selected from one or more selected from the group consisting of a hydroxyl group, a halogen, a nitro group, a cyano group, an alkoxy group, a cycloalkyl group, Heterocyclyl, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or - Substituted by a substituent of NR ⁶ C(O)R ⁷ ;

R ^{2 is} selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, cyano, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ , wherein the alkyl group, The alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl group is further optionally further selected from one or more selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy , haloalkyl, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C(O) R ⁸ , -SO Substituted by a substituent of ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ ; when A _{3 is} selected from N, R ² is absent;

R ^{3 is} each independently selected from the group consisting of a hydrogen atom, an alkyl group, a halogen, a hydroxyl group, an alkoxy group, a cyano group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, -NR ⁶ R ⁷ , -C (O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ , wherein the alkyl group, alkoxy group a cycloalkyl, heterocyclyl, aryl or heteroaryl group optionally further selected from one or more selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkoxy, haloalkyl, haloalkoxy, cycloalkyl , heterocyclyl, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or Substituted by a substituent of -NR ⁶ C(O)R ⁷ ;

R ⁴ are each independently selected from the group consisting of a hydrogen atom, an alkyl group, a halogen, a hydroxyl group, an alkoxy group, a cyano group, a nitro group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, -NR ⁶ R ⁷ , -C (O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ , wherein the alkyl group, alkoxy group a cycloalkyl, heterocyclyl, aryl or heteroaryl group optionally further selected from one or more selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkoxy, haloalkyl, haloalkoxy, cycloalkyl , heterocyclyl, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or Substituted by a substituent of -NR ⁶ C(O)R ⁷ ;

R ^{5 is} each independently selected from the group consisting of a hydrogen atom, an alkyl group, a halogen, a hydroxyl group, an alkoxy group, a cyano group, a nitro group, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C(O)R ⁸ And -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ , wherein said alkyl or alkoxy group is further optionally further selected from one or more selected from the group consisting of hydroxyl groups, halogens, Nitro, cyano, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C Substituting (O) a substituent of R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ ;

R ^{6 is} selected from a hydrogen atom or an alkyl group;

R ^{7 is} selected from a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group or a heteroaryl group, wherein the alkyl group, cycloalkyl group, aryl group or heteroaryl group is further optionally further selected from one or more selected from a hydroxyl group. , halogen, haloalkyl, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁹ R ¹⁰ , -C(O)R ⁹ R ¹⁰ , Substituted with a substituent of -C(O)R ¹¹ , -SO ₂ R ¹¹ , -C(O)OR ¹¹ or -NR ⁹ C(O)R ¹⁰ ;

Alternatively, R ⁶ and R ⁷ together with the N atom to which they are attached form a 4 to 8 membered heterocyclic group, wherein said heterocyclic group contains one or more N, O, S(O) _q atoms, and said The heterocyclic group is further optionally further selected from one or more selected from the group consisting of alkyl, halogen, hydroxy, cyano, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁹ R ¹⁰ ,- Substituted by a substituent of C(O)R ⁹ R ¹⁰ , -C(O)R ¹¹ , -SO ₂ R ¹¹ , -C(O)OR ¹¹ or -NR ⁹ C(O)R ¹⁰ ;

R ^{8 is} selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, cycloalkyl group, heterocyclic group, aryl group or heteroaryl group is further selectively further One or more selected from the group consisting of hydroxyl, halogen, haloalkyl, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁹ R ¹⁰ , -C ( O) substituted with a substituent of R ⁹ R ¹⁰ , -C(O)R ¹¹ , -SO ₂ R ¹¹ , -C(O)OR ¹¹ or -NR ⁹ C(O)R ¹⁰ ;

R ⁹ , R ¹⁰ and R ¹¹ are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group Or a heteroaryl group is further optionally further selected from one or more selected from the group consisting of hydroxyl, halogen, haloalkyl, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, Substituted by a substituent of a carboxylic acid or a carboxylic acid ester;

m is 0, 1, 2, 3, 4 or 5;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

q is 0, 1 or 2.

A preferred embodiment of the invention is a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, which is a compound of the formula (II) Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

Wherein: R ¹ to R ⁵ , m, n and p are as defined in the formula (I).

A preferred embodiment of the invention is a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, which is a compound of the formula (III) Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

Wherein: R ¹ to R ⁵ , m, n and p are as defined in the formula (I).

A preferred embodiment of the invention is a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, which is a compound of the formula (IV) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

Wherein: R ¹ to R ⁵ , m, n and p are as defined in the formula (I).

A preferred embodiment of the invention is a compound of the formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound of the formula (V) Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

Wherein: R ¹ to R ⁵ , m, n and p are as defined in the formula (I).

A preferred embodiment of the invention is a compound of the formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound of the formula (VI) Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

Wherein: the definition of R ^5, m, n and p are as R ¹ ~ the general formula (I).

A preferred embodiment of the invention is a compound of the formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound of the formula (VII) Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

Wherein: R ¹ to R ⁵ , m, n and p are as defined in the formula (I).

A preferred embodiment of the invention is a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, which is a compound of the formula (VIII) Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

Wherein: the definition of R ^5, m, n and p are as R ¹ ~ the general formula (I).

A preferred embodiment of the invention is a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, which is a compound of the formula (IX) Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

Wherein: R ¹ to R ⁵ , m, n and p are as defined in the formula (I).

A preferred embodiment of the invention is a compound of the formula (I) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, which is a compound of the formula (X) Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

Wherein: R ¹ to R ⁵ , m, n and p are as defined in the formula (I).

A preferred embodiment of the invention is a compound of the formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound of the formula (XI) Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

Wherein: R ¹ to R ⁵ , m, n and p are as defined in the formula (I).

A preferred embodiment of the invention is a compound of any one of the formulae (I) to (XI), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein: R ¹ It is selected from a C _3-6 alkyl group, preferably a n-propyl group.

A preferred embodiment of the invention is a compound of any one of the formulae (I) to (XI), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ^{2 is} selected From a phenyl group, wherein the phenyl group is optionally further substituted with one or more substituents of an alkyl group, a halogen, a cyano group, a nitro group, an alkoxy group, a halogenated alkyl group or a halogenated alkoxy group, further preferred embodiments Wherein the phenyl group is further substituted by one or more methyl, trifluoromethyl or trifluoromethoxy groups.

A preferred embodiment of the invention is a compound of any one of the formulae (I) to (XI), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ^{2 is} selected From a 5- to 8-membered heteroaryl group, wherein said heteroaryl group is further optionally further substituted with one or more alkyl, halo, cyano, nitro, alkoxy, haloalkyl or haloalkoxy groups. Replace.

A preferred embodiment of the invention is a compound of any one of the formulae (I) to (XI), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R ^{2 is} further Selected from pyrrole, furan, thiophene, pyrazole, imidazole, thiazole, benzimidazole, benzofuran, or benzoxazole, wherein the pyrrole, furan, thiophene, pyrazole, imidazole, thiazole, benzimidazole, The benzofuran or benzoxazole is optionally further substituted with one or more substituents of an alkyl, halogen, cyano, nitro or alkoxy group, wherein said alkyl or alkoxy group is selective Further substituted by one or more halogen substituents, said halogen is preferably F.

A preferred embodiment of the invention is a compound of any one of the formulae (I) to (XI), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ^{2 is} selected From an alkynyl group, wherein the alkynyl group is further substituted with a cycloalkyl group, wherein the cycloalkyl group is preferably a cyclopropyl group.

A preferred embodiment of the invention is a compound of any one of the formulae (I) to (XI), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ^{3 is} selected From the alkoxy group, wherein the alkoxy group is optionally further substituted with one or more substituents selected from the group consisting of alkyl, halogen, cyano, nitro or alkoxy.

A preferred embodiment of the invention is a compound of any one of the formulae (I) to (XI), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ^{3 is} selected From fluoroalkoxy, preferably trifluoromethoxy or trifluoroethoxy.

A preferred embodiment of the invention is a compound of any one of the formulae (I) to (XI), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R ^{3 is} attached To 3 (meta) or 4 (para), m is 1.

A preferred embodiment of the invention is a compound of any one of the formulae (I) to (XI), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R ^{4 is} selected From a hydrogen atom, a halogen or an alkyl group.

A preferred embodiment of the invention is a compound of any one of the formulae (I) to (XI), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R ^{4 is} selected Since F, n is 1.

A preferred embodiment of the invention is a compound of any one of formula (I), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof,

among them:

A _{3 is} selected from C;

R ^{1 is} selected from n-propyl;

R ^{2 is} selected from alkyl, halogen, cyano, nitro, alkoxy, haloalkyl, haloalkoxy, phenyl or 5- to 8-membered heteroaryl, alkyl, alkoxy, phenyl or The 5- to 8-membered heteroaryl group is optionally further substituted with one or more substituents of an alkyl group, a halogen, a cyano group, a nitro group, an alkoxy group, a halogenated alkyl group or a halogenated alkoxy group;

R ^{3 is} selected from the group consisting of trifluoromethoxy;

R ^{4 is} selected from a hydrogen atom or a halogen;

R ⁵ are each independently selected from a hydrogen atom, an alkyl group, a halogen, an alkoxy group, a halogenated alkyl group or a halogenated alkoxy group;

m is 0, 1 or 2;

n is 0, 1, or 2;

p is 0, 1, or 2.

Typical compounds of the invention include, but are not limited to:

Typical compounds of the invention include, but are not limited to: Or a stereoisomer, tautomer, mixture tautomer thereof or a pharmaceutically acceptable salt thereof.

Typical compounds of the invention include, but are not limited to: Or a stereoisomer, tautomer, mixture tautomer thereof or a pharmaceutically acceptable salt thereof.

Further, the present invention provides a process for the preparation of a compound of the formula (I), or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, the process comprising: The general formula (IC) and the general formula (ID) or a salt thereof are reacted to obtain a compound of the formula (IA); The compound of the formula (IA) is reacted with the formula (IB), and the obtained compound is further hydrolyzed to obtain a compound of the formula (I): wherein: L _{1 is} selected from -C(O)X; L _{2 is} selected from -NH ₂ ; From a hydroxyl group or a halogen; R ^{c is} selected from an alkyl group; L is selected from -NH-C(O)-; and R ¹ to R ⁵ , A ₁ to A ₅ , m, n and p are as defined in the general formula (I) Said in the middle.

Further, the present invention provides a process for the preparation of a compound of the formula (I), or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, the process comprising: The general formula (IC) and the general formula (IB) or a salt thereof are reacted to obtain a compound of the general formula (IE); The reaction of general formula (IE) of the general formula (ID) or a salt thereof, further hydrolyzing the compound obtained, to give compounds of general formula (the I); wherein: X is selected from hydroxy or halo; R ^c is selected from an alkyl group; L ₁ is selected from -NH ₂ ; L _{2 is} selected from -C(O)X; L is selected from -C(O)-NH-; and R ¹ to R ⁵ , A ₁ -A ₅ , m, n and p are as defined Said in (I).

The present invention provides a compound of the formula (IA): or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof: Wherein: L _{1 is} selected from -C(O)X; X is selected from hydroxy or halogen; R ^{c is} selected from alkyl; and R ¹ , R ³ , R ⁴ , m and n are as defined in formula (I) Said.

Typical compounds of formula (IA) include, but are not limited to: Or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof.

Typical compounds of formula (IA) include, but are not limited to: Or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof.

Typical compounds of formula (IA) include, but are not limited to: Or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof.

The present invention provides a compound of the formula (IE) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof: Wherein: X is selected from a hydroxyl group or a halogen; L is selected from -C(O)-NH-; and R ¹ to R ⁵ , A ₁ to A ₅ , m, n and p are as defined in the formula (I) .

Typical compounds of the general formula (IE) include, but are not limited to: Or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof.

The present invention provides a process for the preparation of a compound of the formula (IIA), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, the process comprising: The compound of the formula (IIa) is reacted with the compound of the formula (IIb) under basic conditions to give the formula (IIc); The compound of the formula (IIc) is hydrolyzed under basic conditions to give a compound of the formula (IId); The compound of the formula (IId) is reacted with the compound of the formula (IIe) in the presence of a condensation reagent to give a compound of the formula (IIf); Hydrolysis of the compound of the formula (IIf) under basic conditions gives the compound of the formula (IIA); wherein: X is selected from a hydroxyl group or a halogen; R ^a , R ^b and R ^c are each independently selected from an alkyl group; R ¹ , R ³ , R ⁴ , m and n are as defined in the general formula (I).

In the above preparation method, the basic condition is provided by an organic base or an inorganic base selected from the group consisting of diisopropylethylamine, pyridine, triethylamine, acridine, N-methylpyridazine, 4-dimethylaminopyridine or Potassium tert-butoxide, preferably diisopropylethylamine, triethylamine or potassium t-butoxide; the inorganic base is selected from the group consisting of sodium carbonate, potassium carbonate, cesium carbonate, sodium hydride, sodium hydroxide, potassium hydroxide, hydrogen Lithium oxide or potassium hydride, preferably sodium hydroxide or lithium hydroxide.

In the above preparation method, the condensation reagent includes, but is not limited to, bis(2-oxo-3-oxazolidinyl)phosphorus chloride, N,N-dicyclohexylcarbodiimide, N,N-diiso Propylcarbodiimide, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, o-benzotriazole-N,N,N'N'-tetramethylurea Borate ester (TBTU), preferably 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride or bis(2-oxo-3-oxazolidinyl)phosphorus Chlorine.

The present invention provides a process for the preparation of a compound of the formula (IIIA), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, the process comprising: The compound of the formula (IIIa) is reacted in the presence of tetraisopropyl titanate and ammonia methanol to obtain the formula (IIIb); The condensation reaction of the compound of the formula (IIIb) with the formula (IIIc) gives the compound of the formula (IIId); The compound of the formula (IIId) is subjected to a hydrolysis reaction under acidic conditions to obtain a compound of the formula (IIIA): wherein: X is selected from a hydroxyl group or a halogen; R ^a , R ^b and R ^{c are} selected from an alkyl group; and R ¹ to R ⁵ , A ₁ ~ A ₅ , m, n and p are as defined in the general formula (III).

In the above production method, the acidic condition is provided by an inorganic acid or an organic acid selected from hydrochloric acid or phosphoric acid.

Furthermore, the present invention provides a pharmaceutical composition comprising an effective amount of a compound according to any one of the formulae (I) to (III), or a stereoisomer, tautomer thereof or A pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, excipient or combination thereof.

The present invention provides a method for inhibiting a glycosidic receptor in vitro, the method comprising the step of administering the glycoside receptor to any one of the formulae (I) to (III) or a stereoisomer thereof. The isomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, is contacted.

The present invention provides a compound according to any one of the above formulas (I) to (III), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for the preparation of type I diabetes, Use in drugs for type 2 diabetes, hyperglycemia, obesity, or insulin resistance.

The present invention provides a compound according to any one of the above formulas (I) to (III), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, which is useful in the preparation of a glycoside Use in a body antagonist or inverse agonist.

The present invention provides a compound according to any one of the above formulas (I) to (III), or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for the preparation of a hyperlipemia Use in drugs for diseases, dyslipidemia, hypercholesterolemia, atherosclerosis, and metabolic syndrome.

The compound of any one of the above formulas (I) to (III), or a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, can inhibit a glycoside receptor in vitro Therefore, it can be used to prepare a glycoside receptor antagonist or an inverse agonist, and the present invention further provides that it can be used for treating type I diabetes, type II diabetes, hyperglycemia, obesity, insulin resistance, hyperlipemia. Or a method of dyslipidemia, hypercholesterolemia, atherosclerosis or metabolic syndrome, the method comprising administering to the animal a therapeutically effective amount of a compound of any one of the formulas (I) to (III) of the present invention Or a step of a stereoisomer, tautomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

Unless otherwise stated, some of the terms used in the specification and claims of the present invention are defined as follows:

When "alkyl" as a group or part of a group is meant to include C ₁ -C ₂₀ linear or branched aliphatic hydrocarbon group with a chain. Preferably a C ₁ -C1 ₀ alkyl group, more preferably is C ₁ -C ₆ alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, sec-butyl, n-pentyl, 1, 1-di Methylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1 -ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethyl Butyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl Wait. The alkyl group may be optionally substituted or unsubstituted.

"Alkynyl" as a group or part of a group refers to an aliphatic hydrocarbon group containing a carbon-carbon triple bond, which may be straight or branched. Preferably, a C ₂ -C ₁₀ alkynyl group is selected, more preferably a C ₂ -C ₆ alkynyl group, still more preferably a C ₂ -C ₄ alkynyl group. Examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, and the like. An alkynyl group can be optionally substituted or unsubstituted.

"Cycloalkyl" means a saturated or partially saturated monocyclic, fused, bridged, and spiro carbon ring, ie, comprising a monocyclic cycloalkyl, a fused cycloalkyl, a bridged cycloalkyl, and a spirocycloalkyl. It is preferably a C ₃ -C ₁₂ cycloalkyl group, more preferably a C ₃ -C ₈ cycloalkyl group, still more preferably a C ₃ -C ₆ cycloalkyl group. Examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene The alkenyl group, the cyclooctyl group and the like are preferably a cyclopropyl group or a cyclohexenyl group.

"Spirocycloalkyl" means a polycyclic group of 5 to 18 members, two or more cyclic structures, and a single ring sharing a carbon atom (referred to as a spiro atom), and the ring contains one or more A double bond, but none of the rings have a fully conjugated π-electron aromatic system. It is preferably from 6 to 14 members, more preferably from 7 to 10 members. The spirocycloalkyl group is classified into a monospiro, a spiro- or a spirocycloalkyl group, preferably a mono- and bi-spirocycloalkyl group, more preferably 4 yuan, depending on the number of common spiro atoms between the ring and the ring. 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan. Non-limiting examples of "spirocycloalkyl" include, but are not limited to, spiro[4.5]decyl, spiro[4.4]decyl, spiro[3.5]decyl, spiro[2.4]heptyl.

"Fused cycloalkyl" means 5 to 18 members, an all-carbon polycyclic group containing two or more cyclic structures that share a carbon atom with each other, and one or more rings may contain one or more double bonds, However, none of the rings have a fully conjugated π-electron aromatic system, preferably 6 to 12 members, more preferably 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl group, preferably a bicyclic or tricyclic ring, more preferably a 5 member/5 member or a 5 member/6 member bicycloalkyl group. . Non-limiting examples of "fused cycloalkyl" include, but are not limited to, bicyclo[3.1.0]hexyl, bicyclo[3.2.0]hept-1-enyl, bicyclo[3.2.0]heptyl, Decalinyl or tetradecafluorophenanyl.

"Bridge cycloalkyl" means 5 to 18 members, containing two or more cyclic structures, sharing two all-carbon polycyclic groups that are not directly bonded to each other, and one or more rings may contain one or A plurality of double bonds, but none of the rings have a fully conjugated π-electron aromatic system, preferably 6 to 12 members, more preferably 7 to 10 members. It is preferably from 6 to 14 members, more preferably from 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl group, preferably a bicyclic ring, a tricyclic ring or a tetracyclic ring, more preferably a bicyclic ring or a tricyclic ring. Non-limiting examples of "bridged cycloalkyl" include, but are not limited to: (1s, 4s)-bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, (1s,5s)-di Ring [3.3.1] fluorenyl, bicyclo [2.2.2] octyl, (1r, 5r)-bicyclo[3.3.2] fluorenyl.

The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocyclyl ring, wherein the ring to which the parent structure is attached is a cycloalkyl group, non-limiting examples include indanyl, tetrahydronaphthalene Base, benzocycloheptyl and the like. The cycloalkyl group can be optionally substituted or unsubstituted.

"Heterocyclyl", "heterocyclic" or "heterocyclic" are used interchangeably herein to refer to a non-aromatic heterocyclic group wherein one or more of the ring-forming atoms are heteroatoms such as oxygen, The nitrogen, sulfur atom and the like include a monocyclic ring, a fused ring, a bridged ring and a spiro ring, that is, a monocyclic heterocyclic group, a fused heterocyclic group, a bridged heterocyclic group and a spiroheterocyclic group. It preferably has a 5- to 7-membered monocyclic ring or a 7- to 10-membered double- or tricyclic ring which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulfur. Examples of "heterocyclyl" include, but are not limited to, morpholinyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxo-thiomorpholinyl, acridinyl, 2-oxo- Acridinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, pyridazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl and pyridazinyl. The heterocyclic group may be optionally substituted or unsubstituted.

"Spiroheterocyclyl" means a polycyclic group of 5 to 18 members, two or more cyclic structures, and a single ring sharing one atom with each other, and the ring contains one or more double bonds, but no An aromatic system having a fully conjugated π-electron, wherein one or more ring atoms are selected from the group consisting of nitrogen, oxygen or S(O) _m (where m is selected from 0, 1 or 2), and the remaining ring atoms are carbon. It is preferably from 6 to 14 members, more preferably from 7 to 10 members. The spiroheterocyclyl group is classified into a monospiroheterocyclic group, a dispiroheterocyclic group or a polyspiroheterocyclic group, preferably a monospiroheterocyclic group and a double spiro heterocyclic ring, depending on the number of common spiro atoms between the ring and the ring. base. More preferably, it is 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiro heterocyclic group. Non-limiting examples of "spiroheterocyclyl" include, but are not limited to, 1,7-dioxaspiro[4.5]fluorenyl, 2-oxa-7-azaspiro[4.4]decyl, 7-oxo Heterospiro[3.5]decyl and 5-oxaspiro[2.4]heptyl.

"Fused heterocyclic group" means an all-carbon polycyclic group containing two or more cyclic structures that share a pair of atoms with each other, and one or more rings may contain one or more double bonds, but none of the rings have complete A conjugated π-electron aromatic system in which one or more ring atoms are selected from nitrogen, oxygen or S(O) _m (where m is an integer from 0 to 2) heteroatoms, the remaining ring atoms being carbon. It is preferably from 6 to 14 members, more preferably from 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic ring, more preferably a 5 member/5 element or a 5 member/6 member bicyclic ring hetero Ring base. Non-limiting examples of "fused heterocyclic groups" include, but are not limited to, octahydropyrrolo[3,4-c]pyrrolyl, octahydro-1H-isoindenyl, 3-azabicyclo[3.1. 0] hexyl, octahydrobenzo[b][1,4]dioxine.

"Bridge heterocyclyl" means 5 to 14 members, 5 to 18 members, containing two or more cyclic structures, sharing two polycyclic groups which are not directly connected to each other, and one or more rings may be used. An aromatic system containing one or more double bonds, but none of which has a fully conjugated π-electron, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) _q (where q is an integer from 0 to 2) Of the heteroatoms, the remaining ring atoms are carbon. It is preferably from 6 to 14 members, more preferably from 7 to 10 members. Depending on the number of constituent rings, it may be classified into a bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic group, preferably a bicyclic ring, a tricyclic ring or a tetracyclic ring, and more preferably a bicyclic ring or a tricyclic ring. Non-limiting examples of "fused heterocyclic groups" include, but are not limited to, 2-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.2]octyl and 2-aza-di Ring [3.3.2] sulfhydryl.

The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring wherein the ring to which the parent structure is attached is a heterocyclic group. The heterocyclic group may be optionally substituted or unsubstituted.

"Aryl" means a carbocyclic aromatic system containing one or two rings wherein the rings may be joined together in a fused manner. The term "aryl" includes aryl groups such as phenyl, naphthyl, tetrahydronaphthyl. Preferably, the aryl group is a C ₆ -C ₁₀ aryl group, more preferably the aryl group is a phenyl group and a naphthyl group, and still more preferably a phenyl group. The aryl group may be optionally substituted or unsubstituted. The "aryl" may be fused to a heteroaryl, heterocyclyl or cycloalkyl group, wherein the parent structure is attached to an aryl ring, non-limiting examples include, but are not limited to: with .

"Heteroaryl" means an aromatic 5 to 6 membered monocyclic or 9 to 10 membered bicyclic ring which may contain from 1 to 4 atoms selected from nitrogen, oxygen and/or sulfur. Examples of "heteroaryl" include, but are not limited to, furyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl , oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzo-di Oxolyl, benzimidazolyl, fluorenyl, isodecyl, 1,3-dioxo-isoindolyl, quinolyl, oxazolyl, benzisothiazolyl, benzo Oxazolyl and benzoisoxazolyl. The heteroaryl group can be optionally substituted or unsubstituted. The heteroaryl ring can be fused to an aryl, heterocyclic or cycloalkyl ring wherein the ring to which the parent structure is attached is a heteroaryl ring, non-limiting examples include, but are not limited to: with .

"Alkoxy" means a group of (alkyl-O-). Among them, the alkyl group is defined in the relevant definition herein. Preferred is a C ₁ -C ₆ alkoxy group. Examples thereof include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy and the like.

"Hydroxy" refers to an -OH group.

"Halogen" means fluoro, chloro, bromo and iodo, preferably chloro, bromo and iodo.

"Amino" means -NH ₂ .

"Cyano" means -CN.

"Nitro" means -NO ₂ .

"Benzyl" refers to -CH ₂ - phenyl.

"Carboxy" refers to -C(O)OH.

"Carboxylic acid ester group" means -C(O)O(alkyl) or (cycloalkyl) wherein alkyl, cycloalkyl are as defined above.

"Substituted" refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently of each other, substituted by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art will be able to determine (by experiment or theory) substitutions that may or may not be possible without undue effort. For example, an amino group or a hydroxyl group having a free hydrogen may be unstable when combined with a carbon atom having an unsaturated (e.g., olefinic) bond.

As used herein, "substituted" or "substituted", unless otherwise indicated, means that the group may be substituted by one or more groups selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy. , alkylthio, alkylamino, halogen, sulfhydryl, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkane Thio, heterocycloalkylthio, amino, haloalkyl, hydroxyalkyl, carboxyl, carboxylate, =O, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ , wherein R ⁶ , R ⁷ and R ⁸ are as defined in the formula (I).

The use of definitions and conventions of stereochemistry in the present invention generally refers to the following documents:

SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-HillBook Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York 1994. The compounds of the invention may contain asymmetric centers or chiral centers, and thus different stereoisomers are present. All stereoisomeric forms of the compounds of the invention, including but in no way limited to diastereomers, enantiomers, atropisomers and mixtures thereof, such as racemic mixtures, form part of the present invention. Diastereomers can be separated into individual diastereomers by chromatography, crystallization, distillation or sublimation based on their physicochemical differences. The enantiomers can be converted into diastereomeric mixtures by separation, in the form of a suitable optically active compound (for example, a chiral auxiliary such as a chiral alcohol or Mosher's ruthenium chloride). The reaction, separation of the diastereomers, and conversion of the individual diastereomers to the corresponding pure enantiomers. The intermediates and compounds of the invention may also exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Many organic compounds exist in optically active forms, that is, they have the ability to rotate planes of plane polarized light. In describing an optically active compound, the first code D, L or R, S is used to indicate the absolute configuration of the molecular chiral center. The first code d, l or (+), (-) is used to name the symbol of the rotation of the plane polarized light of the compound, (-) or l means that the compound is left-handed, and the first code (+) or d means that the compound is right-handed. . The atoms or radicals of these stereoisomers are connected in the same order, but their stereostructures are different. A particular stereoisomer can be an enantiomer, and a mixture of isomers is often referred to as a mixture of enantiomers. The 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may result in no stereoselectivity or stereospecificity during the chemical reaction. The terms "racemic mixture" and "racemate" refer to a mixture of two enantiomers of the same molar, lacking optical activity.

"Tautomer" or "tautomeric form" means that the isomers of the structure of different energies can be converted into each other by a low energy barrier. For example, proton tautomers (i.e., proton-shifted tautomers) include interconversions by proton transfer, such as keto-enol and imine-enamine isomerization. The valence (valence) tautomer includes the interconversion of recombination bond electrons. Unless otherwise indicated, the structural formulae described herein include all isomeric forms (e.g., enantiomeric, diastereomeric, and geometric isomerism): for example, R, S configurations containing asymmetric centers , (Z), (E) isomer of double bond, and conformational isomer of (Z), (E). Thus, individual stereochemical isomers of the compounds of the invention, or enantiomers, diastereomers, or mixtures of geometric isomers thereof, are within the scope of the invention.

"Pharmaceutically acceptable salt" refers to certain salts of the above compounds which retain their original biological activity and are suitable for pharmaceutical use. The pharmaceutically acceptable salt of the compound represented by the formula (I) may be a metal salt, an amine salt formed with a suitable acid, the metal salt is preferably an alkali metal or an alkaline earth metal salt, and suitable acids include inorganic acids and organic acids. For example, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, malic acid, Maleic acid, mandelic acid, methanesulfonic acid, nitric acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, and the like. Preferred are hydrochloric acid, hydrobromic acid, phosphoric acid and sulfuric acid, more preferably hydrochloride.

"Pharmaceutical composition" means a mixture comprising one or more of the compounds described herein, or a physiologically pharmaceutically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as physiologically pharmaceutically acceptable carriers and Shape agent. The purpose of the pharmaceutical composition is to promote the administration of the organism, which facilitates the absorption of the active ingredient and thereby exerts biological activity.

Method for synthesizing the compound of the present invention

In order to accomplish the object of the present invention, the present invention adopts the following technical solutions:

The preparation method of the compound of the formula (II) or a salt thereof of the present invention comprises the following steps:

The compound of the formula (IIa) is reacted with the compound of the formula (IIb) under basic conditions to obtain the formula (IIc); the compound of the formula (IIc) is hydrolyzed under basic conditions to give a compound of the formula (IId); The compound of the formula (IId) is reacted with the compound of the formula (IIe) or a salt thereof in the presence of a condensation reagent to obtain a compound of the formula (IIf); the compound of the formula (IIf) is hydrolyzed under basic conditions and acidified to give a compound of the formula (IIA); the compound of the formula (IIA) is reacted with the compound of the formula (IIB) and selectively hydrolyzed to give a compound of the formula (II). Wherein: X is selected from a hydroxyl group or a halogen; R ^a , R ^b and R ^{c are} selected from an alkyl group; and R ¹ to R ⁵ , A ₁ to A ₅ , m, n and p are as defined in the formula (II) Said.

In the above preparation method, the basic condition is provided by an organic base or an inorganic base selected from the group consisting of diisopropylethylamine, pyridine, triethylamine, acridine, N-methylpyridazine, 4-dimethylaminopyridine or Potassium tert-butoxide, preferably diisopropylethylamine, triethylamine or potassium t-butoxide; the inorganic base is selected from the group consisting of sodium carbonate, potassium carbonate, cesium carbonate, sodium hydride, sodium hydroxide, potassium hydroxide, hydrogen Lithium oxide or potassium hydride, preferably sodium hydroxide or lithium hydroxide.

In the above preparation method, the condensation reagent includes, but is not limited to, bis(2-oxo-3-oxazolidinyl)phosphorus chloride, N,N-dicyclohexylcarbodiimide, N,N-diiso Propylcarbodiimide, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, o-benzotriazole-N,N,N'N'-tetramethylurea Borate ester (TBTU), preferably 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride or bis(2-oxo-3-oxazolidinyl)phosphorus Chlorine.

The preparation method of the compound of the formula (III) or a salt thereof of the present invention comprises the following steps:

The compound of the formula (IIIa) is reacted in the presence of tetraisopropyl titanate and ammonia methanol to obtain the formula (IIIb); the compound of the formula (IIIb) is subjected to a condensation reaction with the formula (IIIc) to obtain a compound of the formula (IIId). a compound; the compound of the formula (IIId) is subjected to a hydrolysis reaction under acidic conditions to obtain a compound of the formula (IIIA); the compound of the formula (IIIA) is reacted with the compound of the formula (IIe) or a salt thereof, and selectively hydrolyzed to obtain a compound of the formula (III). Wherein: X is selected from a hydroxyl group or a halogen; R ^a , R ^b and R ^{c are} selected from an alkyl group; and R ¹ to R ⁵ , A ₁ to A ₅ , m, n and p are as defined in the formula (III) Said.

In the above preparation method, the basic condition is provided by an organic base or an inorganic base selected from the group consisting of diisopropylethylamine, pyridine, triethylamine, acridine, N-methylpyridazine, 4-dimethylaminopyridine or Potassium tert-butoxide, preferably diisopropylethylamine, triethylamine or potassium t-butoxide; the inorganic base is selected from the group consisting of sodium carbonate, potassium carbonate, cesium carbonate, sodium hydride, sodium hydroxide, potassium hydroxide, hydrogen Lithium oxide or potassium hydride, preferably sodium hydroxide or lithium hydroxide.

The acidic conditions are provided by an inorganic or organic acid selected from the group consisting of hydrochloric acid or phosphoric acid.

In the above preparation method, the condensation reagent includes, but is not limited to, bis(2-oxo-3-oxazolidinyl)phosphorus chloride, N,N-dicyclohexylcarbodiimide, N,N-diiso Propylcarbodiimide, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, o-benzotriazole-N,N,N'N'-tetramethylurea Borate ester (TBTU), preferably 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride or bis(2-oxo-3-oxazolidinyl)phosphorus Chlorine.

The invention is further described in the following examples, but these examples are not intended to limit the scope of the invention.

Example

The examples show the preparation of representative compounds represented by formula (I) and related structural identification data. It is to be understood that the following examples are intended to illustrate the invention and not to limit the invention. ^{The 1} H NMR spectrum was measured using a Bruker instrument (400 MHz) and the chemical shift was expressed in ppm. The internal standard (0.00 ppm) of tetramethyl decane was used. ¹ H NMR representation: s = singlet, d = doublet, t = triplet, m = multiplet, br = broadened, dd = doublet of doublet, dt = doublet of triplet. If a coupling constant is provided, its unit is Hz.

Mass spectrometry was measured by LC/MS, and the ionization method was ESI or APCI.

The thin layer chromatography gelatin plate uses Yantai Yellow Sea HSGF254 or Qingdao GF254 silicone plate. The specification of the silica gel plate used for thin layer chromatography (TLC) is 0.15mm~0.2mm. The specification for thin layer chromatography separation and purification is 0.4mm. ~0.5mm.

Column chromatography generally uses Yantai Huanghai Silicone 200-300 mesh silicone as a carrier.

In the following examples, all temperatures are in degrees Celsius unless otherwise indicated, and unless otherwise indicated, the various starting materials and reagents are either commercially available or synthesized according to known methods, and the commercially available starting materials and reagents are not directly purified. For use, unless otherwise indicated, commercial suppliers include, but are not limited to, Aldrich Chemical Company, ABCR GmbH & Co. KG, Acros Organics, Guangzan Chemical Technology Co., Ltd. and Jingyan Chemical Technology Co., Ltd., etc.

CD ₃ OD: Deuterated methanol.

CDCl ₃ : deuterated chloroform.

DMSO-d6: deuterated dimethyl adenine.

The argon atmosphere means that the reaction flask is connected to an argon balloon having a volume of about 1 L.

There is no particular description in the examples, and the solution in the reaction means an aqueous solution.

The progress of the reaction in the examples was monitored by thin layer chromatography (TLC). The system used for the reaction was: A: petroleum ether and ethyl acetate system, B: dichloromethane and ethyl acetate system, C: In methylene chloride and methanol systems, the volume ratio of the solvent is adjusted depending on the polarity of the compound.

The system of eluent for column chromatography or thin layer chromatography plates includes: A: petroleum ether and ethyl acetate systems, B: n-hexane and ethyl acetate systems, C: dichloromethane and methanol systems, D: petroleum Ether and methanol systems. The volume ratio of the solvent is adjusted depending on the polarity of the compound, and may be adjusted by adding a small amount of ammonia water, acetic acid or the like.

Example 1

3-(4-((2R,3S)/(2S,3R)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-) 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 1

3-(4-((2R,3S)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2 -(4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 1A

3-(4-((2S,3R)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2 -(4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 1B

first step

Methyl 4-(1-hydroxybutyl)benzoate

Methyl 4-methylmercaptobenzoate 1a (10.00 g, 60.92 mmol) was dissolved in 100 mL of tetrahydrofuran, and the reaction mixture was cooled to -78 ° C, and propyl magnesium bromide 1b (33.50 mL, 67.00 mmol) was added dropwise. After the dropwise addition was completed, the mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with 100 mL of water and extracted with ethyl acetate (100 mL×3). The combined organic phase was washed with saturated aqueous ammonium chloride (200 mL) and sodium chloride (200 mL) Filtration, concentration under reduced pressure, and the residue obtained was purified by silica gel column chromatography (eluent: System A) to give methyl 4-(1-hydroxybutyl)benzoate 1c (7.50 g, colorless liquid) , Yield: 59.1%.

_{^{1 H NMR (400MHz, CDCl 3}} ): δ7.99 (d, J = 8.28 Hz, 2 H) 7.39 (d, J = 8.03 Hz, 2 H) 4.73 (t, J = 6.53 Hz, 1 H) 3.89 ( s, 3 H) 1.80-2.25 (m, 1H) 1.59 - 1.82 (m, 2 H) 1.21 - 1.50 (m, 2 H) 0.92 (t, J = 7.40 Hz, 3 H)

Second step

Methyl 4-(1-bromobutyl)benzoate

Methyl 4-(1-hydroxybutyl)benzoate 1c (7.50 g, 36.00 mmol) was dissolved in 100 mL of dichloromethane and then added with carbon tetrabromide (23.88 g, 72.00 mmol) and triphenylphosphor (18.88 g, 72.00 mmol), stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified and purified by silica gel column chromatography (eluent: system A) to give methyl 4-(1-bromobutyl)benzoate 1d (6.49 g, brown Liquid), yield: 66.5%.

_{^{1 H NMR (400MHz, CDCl 3}} ): δ8.01 (d, J = 8.28 Hz, 2 H) 7.46 (d, J = 8.28 Hz, 2 H) 4.96 (t, J = 7.53 Hz, 1 H) 3.92 ( s, 3 H) 2.23 - 2.28 (m, 1 H) 2.06 - 2.13 (m, 1 H) 1.46 - 1.54 (m, 1 H) 1.29 - 1.37 (m, 1 H) 0.94 (t, J = 7.40 Hz, 3 H)

third step

Tert-butyl 2-(4-(trifluoromethoxy)phenyl)acetate

Magnesium sulfate (21.86 g, 182 mmol) was dissolved in 100 mL of dichloromethane, concentrated sulfuric acid (2.66 mL, 50 mmol) was added dropwise, and stirred for 10 minutes, followed by the addition of 2-(4-(trifluoromethoxy)benzene Acetic acid 1e (10 g, 45.4 mmol) and tert-butanol (4.9 mL, 50 mmol) were stirred at room temperature for 24 hours. The reaction solution was poured into 100 mL of saturated sodium bicarbonate solution, and the mixture was extracted with ethyl acetate (100 mL×3), and the combined organic phase was saturated with ammonium chloride (200 mL) and sodium chloride solution (200) The mixture was washed with EtOAc (3 mL). Phenyl)-tert-butyl acetate 1f (8.84 g, brown liquid), yield: 70.7%.

_{^{1 H NMR (400MHz, CDCl 3}} ): δ7.29 (d, J = 8.28 Hz, 2 H) 7.16 (d, J = 8.03 Hz, 2 H) 3.53 (s, 2 H) 1.44 (s, 9 H)

the fourth step

Methyl 4-(1-(tert-butoxy)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzoate

tert-Butyl 2-(4-(trifluoromethoxy)phenyl)acetate 1f (7.11 g, 25.7 mmol) and potassium t-butoxide (6.98 g, 25.7 mmol) were dissolved in 50 mL of N,N-dimethyl Methyl decylamine was added with methyl 4-(1-bromobutyl)benzoate 1d (6.98 g, 25.7 mmol), and stirred at room temperature for 5 hr. The reaction mixture was diluted with EtOAc (EtOAc) (EtOAc (EtOAc) The residue obtained is purified by silica gel column chromatography (eluent: System A) to give 4-(1-(tert-butoxy)-1-oxo-2-(4-trifluoromethoxy) Methyl phenyl)hexane-3-yl)benzoate 1 g (4.27 g, white solid), yield: 35.6%.

MS m/z (ESI): 410.9 [M-57]

the fifth step

4-(1-(tert-Butoxy)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzoic acid

Methyl 4-(1-(tert-butoxy)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzoate 1 g (4.27 g, 9.2 Methyl) was dissolved in a mixed solvent of 30 mL of tetrahydrofuran and methanol (V/V = 1:1), and added with 5 mL of sodium hydroxide (1.83 g, 45.8 mmol), and stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. Filtration and concentration under reduced pressure, and the obtained residue was purified by silica gel chromatography (eluent: System A) to give 4-(1-(tert-butoxy)-1-oxo-2-(4-) (Trifluoromethoxy)phenyl)hexane-3-yl)benzoic acid 1 h (4 g, white solid).

MS m/z (ESI): 452.46 [M-57]

Step 6

tert-Butyl 3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-(trifluoromethoxy)phenyl)hexanoate 1k

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-(III Fluoromethoxy)phenyl)hexanoic acid tert-butyl ester 1p

((2R,3R)/(2S,3S))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-(three Fluoromethoxy)phenyl)hexanoic acid tert-butyl ester 1q

4-(1-(tert-Butoxy)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzoic acid 1 h (4.00 g, 8.84 mmol) , 3-aminopropionic acid ethyl ester hydrochloride 1j (1.25 g, 10.60 mmol), 1-hydroxybenzotriazole (1.79 g, 13.30 mmol) and 1-ethyl-(3-dimethylaminopropyl) The carbodiimide hydrochloride (2.54 g, 13.30 mmol) was dissolved in 50 mL of tetrahydrofuran, and triethylamine (7.8 mL, 44.2 mmol) was added and stirred at room temperature for 24 hours. The reaction mixture was diluted with 50 mL of EtOAc (EtOAc)EtOAc. The residue was purified by silica gel column chromatography (eluent: System A) to give 3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2 -(4-(Trifluoromethoxy)phenyl)hexanoic acid tert-butyl ester 1k (2.352 g, white solid), which can be further purified by silica gel column chromatography to give slow elution ((2R, 3S) /(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-(trifluoromethoxy)benzene Tert-butyl hexanoate 1p (1.61 g, white solid) and faster elution ((2R,3R)/(2S,3S))-3-(4-((3-ethoxy-3-oxo) Propyl propyl)carbamidyl)phenyl)-2-(4-(trifluoromethoxy)phenyl)hexanoic acid tert-butyl ester 1q (742 mg, white solid), yield: 35.1%.

1k: MS m/z (ESI): 552.9 [M+1]

1p: MS m/z (ESI): 552.9 [M+1]

¹ H NMR (400MHz, CDCl ₃ ) δ = 7.72 (d, J = 8.0 Hz, 2 H), 7.47 (d, J = 8.5 Hz, 2 H), 7.34 (d, J = 8.0 Hz, 2 H), 7.20 (d, J = 8.0 Hz, 2 H), 6.84 (br. s., 1 H), 4.23 - 4.13 (m, 2 H), 3.78 - 3.61 (m, 3 H), 3.20 (dt, J = 3.8, 10.9 Hz, 1 H), 3.27 - 3.14 (m, 1 H), 2.70 - 2.60 (m, 2 H), 1.62 (br. s., 2 H), 1.68 - 1.55 (m, 2 H), 1.27 (t, J = 7.2 Hz, 5 H), 1.05 (s, 9 H), 0.93 (tt, J = 7.8, 15.0 Hz, 2 H), 0.72 - 0.61 (m, 3 H).

1q: MS m/z (ESI): 552.9 [M+1]

¹ H NMR (400MHz, CDCl ₃ ) δ = 7.50 (d, J = 8.0 Hz, 2 H), 7.11 (d, J = 8.5 Hz, 2 H), 6.99 (d, J = 8.0 Hz, 2 H), 6.92 (d, J = 8.3 Hz, 2 H), 6.70 (br. s., 1 H), 4.15 (d, J = 7.0 Hz, 2 H), 3.72 - 3.57 (m, 2 H), 3.28 (br s., 1 H), 2.59 (t, J = 5.6 Hz, 2 H), 1.81 - 1.64 (m, 1 H), 1.87 - 1.60 (m, 2 H), 1.44 (s, 9 H), 1.25 (t, J = 7.2 Hz, 3 H), 1.13 - 1.04 (m, 2 H), 0.87 - 0.80 (m, 3 H).

Seventh step

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-(III Fluoromethoxy)phenyl)hexanoic acid 1m

((2R,3R)/(2S,3S))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-(three Fluoromethoxy)phenyl)hexanoic acid 1s

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( tert-Butyl trifluoromethoxy)phenyl)hexanoate 1p (1.61 g, 2.90 mmol) was dissolved in 20 mL of trifluoroacetic acid and stirred at room temperature for 0.5 h. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: system A) to give ((2R,3S)/(2S,3R))-3-(4- ((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-(trifluoromethoxy)phenyl)hexanoic acid 1 m (1.40 g, pale yellow oil ()), yield: 97.2%.

MS m/z (ESI): 495.9 [M+1]

((2R,3R)/(2S,3S))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( tert-Butyl trifluoromethoxy)phenyl)hexanoate 1q (742.00 mg, 1.35 mmol) was dissolved in dichloromethane (20 mL), trifluoroacetic acid (0.20 mL, 2.69 mmol). Additional 5 mL of trifluoroacetic acid was added and the reaction was continued for 3 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted elution (3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-(trifluoromethoxy)phenyl)hexanoic acid 1s (663.00 mg, pale yellow viscous material ), yield: 99.48%.

MS m/z (ESI): 495.9 [M+1]

Eighth step

3-(4-((2R,3S)/(2S,3R)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-) Ethyl 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamine)propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (80.00 mg, 0.16 mmol), 4'-chloro-2'-methyl-[1,1'-biphenyl]-4-amine 1n (52.00 mg, 0.24 Methyl), 1-hydroxybenzotriazole (43.00 mg, 0.32 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (61 mg, 0.32 mmol) dissolved in 20 Triethylamine (0.14 mL, 0.80 mmol) was added to dichloromethane, and stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted elution ((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl) Ethyl hexane-3-yl)benzylideneamino)propanoate 1t (58.00 mg, white solid), yield: 51.8%.

MS m/z (ESI): 695.8 [M+1]

Step 9

3-(4-((2R,3S)/(2S,3R)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-) 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino) 1-Oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propionic acid ethyl ester 1t (50.00 mg, 0.072 mmol) dissolved in 6 mL A mixed solvent of tetrahydrofuran and methanol (V/V = 1:1) was added to a solution of 1 mL of sodium hydroxide (14.40 mg, 0.36 mmol) with stirring, and stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure. EtOAc EtOAc (EtOAc m. Concentration under reduced pressure, the residue obtained was purified by silica gel column chromatography (eluent: System A) to give 3-(4-((2R,3S)/(2S,3R)-1-((4) '-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane- 3-yl)benzimidamide)propionic acid 1 (4.00 g, white solid), yield: 64.5%.

MS m/z (ESI): 668.7 [M+1]

¹ H NMR (400 MHz, DMSO-d ₆ ) δ 10.07 (s, 1H), 8.45 (s, 1H), 7.76 (d, J = 7.9 Hz, 2H), 7.69 (d, J = 8.4 Hz, 2H) , 7.48 – 7.35 (m, 6H), 7.32 (s, 1H), 7.24 (d, J = 7.9 Hz, 1H), 7.16 – 7.07 (m, 3H), 4.11 (d, J = 11.8 Hz, 1H), 2.47 (s, 2H), 2.14 (s, 3H), 0.96 – 0.89 (m, 2H), 0.85 (t, J = 6.5 Hz, 2H), 0.64 (t, J = 7.4 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-) 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 1 was further prepared by supercritical fluid chromatography (SFC) Equipment and chiral column chiral isomers are resolved (1) chiral column ChiralPak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL / min; The mobile phase A for CO ₂ and B for Ethanol)) was resolved to give 3-(4-((2R,3S)-1-((4'-chloro-2'-methyl-[1,1'-- Biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 1A and 3- (4-((2S,3R)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-() 4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 1B.

1A: MS m/z (ESI): 668.7 [M+1]

1B: MS m/z (ESI): 668.7 [M+1]

Example 2

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6) '-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propionic acid 2

3-(4-((2R,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6'-trimethyl-) [1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propionic acid 2A

3-(4-((2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6'-trimethyl-) [1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propionic acid 2B

first step

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6) '-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (100.00 mg, 0.20 mmol), 2',4',6'-trimethyl-[1,1'-biphenyl]-4-amine 2a (63.00 mg , 0.3 mmol), 1-hydroxybenzotriazole (41.00 mg, 0.30 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (43.00 mg, 0.32 mmol) N,N-diisopropylethylamine (0.09 mL, 0.50 mmol) was added to 10 mL of dichloromethane and stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted eluted Oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl) Amino)hexane-3-yl)benzamide amino)ethyl propionate 2b (50.00 mg, white solid), yield: 36.3%.

MS m/z (ESI): 689.9 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6) '-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4', 6'-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzylideneamine)ethyl propionate 2b (50.00 mg, 0.072 mmol) was dissolved in 6 mL of a mixed solvent of tetrahydrofuran and methanol (V/V = 1:1) was added to a solution of 1 mL of sodium hydroxide (14.40 mg, 0.36 mmol) with stirring, and stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc)EtOAc. Concentration under reduced pressure, the residue obtained was purified by silica gel column chromatography (eluent: System B) to give 3-(4-((2R,3S)/(2S,3R)-1-oxo- 2-(4-(Trifluoromethoxy)phenyl)-1-((2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino) Alkyl-3-yl)benzhydrylamino)propanoic acid 2 (20.00 mg, white solid), yield: 42.0%.

MS m/z (ESI): 661.9 [M+1]

¹ H NMR (400 MHz, DMSO-d ₆ ) δ 10.00 (s, 1H), 8.45 (s, 1H), 7.77 (d, J = 7.7 Hz, 2H), 7.69 (d, J = 7.9 Hz, 2H) , 7.52 – 7.31 (m, 6H), 6.96 – 6.79 (m, 4H), 4.11 (d, J = 10.8 Hz, 1H), 3.42 (d, J = 5.8 Hz, 3H), 2.49 – 2.44 (m, 2H) ), 1.84 (s, 5H), 0.95 – 0.80 (m, 4H), 0.65 (t, J = 7.2 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6) '-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzamide amino)propanoic acid 2 further by using supercritical fluid chromatography (SFC), Resolution by preparative equipment and chiral column chiral isomers ((1) chiral column ChiralPak AD, 25×3 cm, 80 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (2 Whelk O1 (S, S), 25 × 3 cm, 65 mL / min; mobile phase A for CO2 and B for Ethanol; and / or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL / min ; mobile phase A for CO2 and B for Ethanol)) is resolved to give 3-(4-((2R,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)- 1-((2',4',6'-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propionic acid 2A ( White solid) and 3-(4-((2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6'-) Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propionic acid 2B (white solid).

2A: MS m/z (ESI): 668.7 [M+1]

2B: MS m/z (ESI): 668.7 [M+1]

Example 3

3-(4-((2R,3S)/(2S,3R)-1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-2-(4-( Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 3

3-(4-((2R,3S)-1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)) Phenyl)hexane-3-yl)benzimidamide)propionic acid 3A

3-(4-((2S,3R)-1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)) Phenyl)hexane-3-yl)benzimidamide)propionic acid 3B

first step

4-(benzofuran-2-yl)aniline

4-iodoaniline 3a (448.00 mg, 2.05 mmol), 2-(benzofuran-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan 3b (500.00 mg, 21.10 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium(II) chloride (1.54 g, 2.11 mmol) and sodium carbonate (652.00 mg, 6.15 mmol) dissolved in 28 In a mixed solvent of mL dimethyl ether, ethanol and water (V/V/V = 5:1:1), the reaction solution was reacted at 100 ° C for 5 hours under argon gas protection. The reaction mixture was concentrated under reduced pressure. EtOAc mjjjjjjj , yield: 35%.

MS m/z (ESI): 210.9 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-2-(4-( Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (80 mg, 0.16 mmol), 4-(benzofuran-2-yl)aniline 3c (50 mg, 0.24 mmol), bis (2-oxo-3- The oxazolidinylphosphine chloride (61 mg, 0.24 mmol) was dissolved in 10 mL of dichloromethane, and then stirred, and then, then, N,N-diisopropylethylamine (0.14 mL, 0.8 mmol) 1 hour. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted eluted ((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzamide Ethyl propionate 3d (61 mg, white solid), yield: 55.6%.

MS m/z (ESI): 687.8 [M+1]

third step

3-(4-((2R,3S)/(2S,3R)-1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-2-(4-( Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-2-(4-) Ethyl (trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoate 3d (60 mg, 0.087 mmol) dissolved in 6 mL of tetrahydrofuran and methanol (V/V = 1:1 In a mixed solvent, 1 mL of lithium hydroxide monohydrate (73 mg, 1.75 mmol) was added with stirring, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was adjusted to pH 3 with 1M hydrochloric acid and extracted with ethyl acetate (50 mL). The combined organic phases were washed with saturated aqueous ammonium chloride (50 mL×2), sodium chloride solution (50 mL) Drying over sodium sulfate, filtration, EtOAc (EtOAc m.) 1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzene Amidino)propionic acid 3 (50 mg, white solid), yield: 87.3%.

MS m/z (ESI): 658.9 [M+1]

_{^{1 H NMR (400MHz, CDCl 3}} ): δ 1 H NMR (400 MHz, DMSO-d 6) δ ppm 7.73 (td, J = 15.56, 8.28 Hz, 8 H) 7.54 - 7.63 (m, 3 H) 7.38 - 7.48 (m, 6 H) 7.21 - 7.28 (m, 2 H) 4.11 (d, J = 11.29 Hz, 1 H) 3.37 - 3.50 (m, 2 H) 2.43 - 2.48 (m, 1 H) 1.23 - 1.32 ( m, 3 H) 1.18 (d, J = 4.77 Hz, 1 H) 0.93 (d, J = 6.53 Hz, 2 H) 0.84 - 0.90 (m, 2 H) 0.65 (t, J = 7.15 Hz, 3 H)

3-(4-((2R,3S)/(2S,3R)-1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-2-(4-( Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 3 is further carried out by using a supercritical fluid chromatography (SFC) method using preparative equipment and a chiral column chiral isomer Resolution (1) Chiral Pak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B for Ethanol) The resolution was carried out to obtain 3-(4-((2R,3S)-1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-2-(4-) Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 3A (white solid) and 3-(4-((2S,3R)-1-((4-(benzene) And furan-2-yl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 3B ( White solid).

3A: MS m/z (ESI): 658.9 [M+1]

3B: MS m/z (ESI): 658.9 [M+1]

Example 4

3-(4-((2R,3S)/(2S,3R)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4 -yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 4

3-(4-((2R,3S)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino)- 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 4A

3-(4-((2S,3R)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino)-) 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 4B

first step

3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-amine

2-Fluoro-4-iodoaniline 4a (5 g, 21.1 mmol), 2,4,6-trimethylphenylboronic acid 4b (3.46 g, 21.1 mmol), 1,1'-bis(diphenylphosphino)di The ferrocene palladium(II) chloride (1.54 g, 2.11 mmol) was dissolved in 100 mL of N,N-dimethylformamide and added to a solution of 20 mL of sodium hydroxide (2.53 g, 63.3 mmol) with stirring. The reaction solution was reacted at 100 ° C for 4 hours under argon gas protection. The reaction mixture was extracted with ethyl acetate (100 mL×3), and the combined organic phase was washed with sodium chloride solution (100 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (eluent: System B) gave 3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-amine 4c (4.8 g, White solid), Yield: 96.2%.

MS m/z (ESI): 230.0 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4 -yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propionic acid ethyl ester

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (5.00 g, 10.09 mmol), 3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-amine 4c (2.31 g, 10.09 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (3.84 g, 15.13 mmol) was dissolved in 50 mL of dichloromethane, and N,N- was added with stirring. Diisopropylethylamine (8.79 mL, 50.45 mmol) was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted elution ((3-Fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethyl) Ethyloxy)phenyl)hexane-3-yl)benzylideneamino)propionic acid ethyl ester 4d (2.10 g, white solid), yield: 29.5%.

MS m/z (ESI): 706.9 [M+1]

third step

3-(4-((2R,3S)/(2S,3R)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4 -yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]- Ethyl 4-amino)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoate 4d (5.20 g, 7.35 Methyl) was dissolved in a mixed solvent of 120 mL of tetrahydrofuran and methanol (V/V = 1:1), and 10 mL of a solution of lithium hydroxide monohydrate (6.10 g, 147 mmol) was added under stirring, and the mixture was stirred at room temperature for 2 hours. Add 500 mL of ethyl acetate, wash with 0.3 M of dilute hydrochloric acid to pH = 5-6, wash with saturated sodium chloride solution (300 mL), and concentrate the organic phase under reduced pressure. Purification by the method (eluent: System A) gave 3-(4-((2R,3S)/(2S,3R)-1-((3-fluoro-2',4',6'-trimethyl) -[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide Propionic acid 4 (4.50 g, white solid), yield: 90.18%.

MS m/z (ESI): 678.9 [M+1]

_{^{1 H NMR (400MHz, CDCl 3}} ): 9.78 (s, 1 H) 8.45 (t, J = 5.14 Hz, 1 H) 7.77 (d, J = 8.03 Hz, 2 H) 7.68 (d, J = 8.53 Hz, 2 H) 7.53 - 7.62 (m, 1 H) 7.41 (dd, J = 13.05, 8.28 Hz, 4 H) 6.82 - 6.94 (m, 2 H) 4.39 (d, J = 11.54 Hz, 1 H) 4.01 (q , J =7.11 Hz, 2 H) 3.38 - 3.47 (m, 2 H) 2.17 - 2.26 (m, 2 H) 1.93 - 2.01 (m, 2 H) 1.83 (d, J =10.29 Hz, 3 H) 1.11 - 1.25 (m, 3 H) 0.79 - 0.93 (m, 4 H) 0.56 - 0.68 (m, 3 H)

3-(4-((2R,3S)/(2S,3R)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4 -yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 4 further by using supercritical fluid chromatography ( SFC) method, using preparative equipment and chiral column chiral isomers for resolution ((1) chiral column ChiralPak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; / or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (3) Whelk O1 (S, S), 25 × 3cm , 70 mL/min; mobile phase A for CO ₂ and B for Ethanol)) was resolved to give 3-(4-((2R,3S)-1-((3-fluoro-2',4',6) '-Trimethyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl) Benzylamino)propionic acid 4A and 3-(4-((2S,3R)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-linked Benzene-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 4B.

4A: MS m/z (ESI): 678.9 [M+1]

¹ H NMR (400MHz, DMSO-d ₆ ) δ = 9.79 (s, 1 H), 8.53 - 8.40 (m, 1 H), 7.79 (d, J = 8.0 Hz, 2 H), 7.70 (d, J = 8.5 Hz, 2 H), 7.58 (t, J = 8.4 Hz, 1 H), 7.43 (dd, J = 8.4, 11.9 Hz, 4 H), 6.94 - 6.82 (m, 3 H), 6.73 (d, J = 8.0 Hz, 1 H), 4.47 - 4.34 (m, 1 H), 3.50 - 3.38 (m, 4 H), 3.17 (s, 2 H), 2.22 (s, 3 H), 1.85 (d, J = 10.0 Hz, 6 H), 1.06 (t, J = 7.0 Hz, 2 H), 0.96 - 0.85 (m, 2 H), 0.64 (d, J = 14.3 Hz, 3 H).

4B: MS m/z (ESI): 678.9 [M+1]

¹ H NMR (400 MHz, DMSO-d ₆ ) δ = 9.80 (s, 1 H), 8.47 (t, J = 5.4 Hz, 1 H), 7.79 (d, J = 8.0 Hz, 2 H), 7.71 (d , J = 8.5 Hz, 2 H), 7.59 (t, J = 8.3 Hz, 1 H), 7.44 (dd, J = 8.3, 12.8 Hz, 4 H), 6.94 - 6.85 (m, 3 H), 6.73 ( d, J = 8.3 Hz, 1 H), 4.42 (d, J = 11.5 Hz, 1 H), 3.52 - 3.30 (m, 6 H), 2.22 (s, 3 H), 1.86 (d, J = 10.5 Hz , 7 H), 1.42 - 1.29 (m, 1 H), 1.19 (br. s., 1 H), 1.06 (t, J = 7.0 Hz, 3 H), 0.91 (d, J = 7.5 Hz, 2 H ), 0.70 - 0.58 (m, 3 H).

Example 5

3-(4-((2R,3S)/(2S,3R)-1-((2-fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2-(4- (trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 5

3-(4-((2R,3S)-1-((2-fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)) Phenyl)hexane-3-yl)benzimidamide)propionic acid 5A

3-(4-((2S,3R)-1-((2-fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)) Phenyl)hexane-3-yl)benzimidamide)propionic acid 5B

first step

3-(4-((2R,3S)/(2S,3R)-1-((2-fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2-(4- (trifluoromethoxy)phenyl)hexane-3-yl)benzamide amino)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (60 mg, 0.12 mmol), 2-fluoro-4-(trifluoromethyl)aniline 5a (25 mg, 0.13 mmol), bis (2-oxo-3) The oxazolidinylphosphine chloride (46 mg, 0.18 mmol) was dissolved in 20 mL of dichloromethane, and triethylamine (0.085 mL, 0.6 mmol) was then stirred and stirred at room temperature for 2 hr. 15 mL of ethyl acetate and 10 mL of water were added to the reaction mixture, pH 1 was adjusted with 3 M hydrochloric acid, and the aqueous layer was extracted with ethyl acetate (15 mL×2), and the combined organic phases were sequentially saturated sodium chloride (10) The mixture was washed with EtOAc (EtOAc m. 2S,3R)-1-((2-fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane- 3-yl)benzamide amino)ethyl propionate 5b (20 mg, white solid), yield: 25.6%.

Second step

3-(4-((2R,3S)/(2S,3R)-1-((2-fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2-(4- (trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-((2-Fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2-(4) -(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide ethyl propionate 5b (20 mg, 0.03 mmol) dissolved in 3 mL of tetrahydrofuran and water (V/V = 2:1) In a mixed solvent, lithium hydroxide monohydrate (3 mg, 0.06 mmol) was added with stirring, and the mixture was stirred at room temperature for 24 hours. The reaction mixture was adjusted to pH = 3 with 1M hydrochloric acid, and extracted with ethyl acetate (15 mL). The combined organic phases were washed with saturated aqueous ammonium chloride (10 mL) and saturated sodium chloride (10 mL) Drying over sodium sulfate, filtration, and EtOAc~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1-((2-Fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzene Methionine) propionic acid 5 (18 mg, white solid), yield: 94.7%.

MS m/z (ESI): 629.8 [M+1]

¹ H NMR (400 MHz, DMSO-d ₆ ): δ 10.08 (br. s., 1 H), 8.45 (br. s., 1 H), 7.85 (br. s., 1 H), 7.76 (d , J = 7.0 Hz, 2 H), 7.69 (d, J = 7.3 Hz, 2 H), 7.59 (d, J = 10.8 Hz, 1 H), 7.42 (br. s., 5 H), 4.47 (d , J = 11.3 Hz, 1 H), 3.56 - 3.42 (m, 5 H), 1.41 - 1.23 (m, 4 H), 0.64 (br. s., 3 H)

3-(4-((2R,3S)/(2S,3R)-1-((2-fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2-(4- (Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 5 compound further by using supercritical fluid chromatography (SFC) method, using preparative equipment and chiral column chiral isomerism Resolution of the body ((1) ChiralPak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3cm, 65 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B for Ethanol)) Resolution was carried out to give 3-(4-((2R,3S)-1-((2-fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2- ( 4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 5A (white solid) and 3-(4-((2S,3R)-1-(2) -fluoro-4-(trifluoromethyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide) Propionic acid 5B (white solid).

5A: MS m/z (ESI): 629.8 [M+1]

5B: MS m/z (ESI): 629.8 [M+1]

Example 6

3-(4-((2R,3S)/(2S,3R)-1-((2,5-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzimidamide)propionic acid 6

3-(4-((2R,3S)-1-((2,5-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane -3-yl)benzamide aminopropionic acid 6A

3-(4-((2S,3R)-1-((2,5-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane -3-yl)benzamide amino)propionic acid 6B

first step

3-(4-((2R,3S)/(2S,3R)-1-((2,5-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Ethyl phenyl)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (80 mg, 0.16 mmol), 2,5-difluoroaniline 6a (33.3 mg, 0.24 mmol), bis(2-oxo-3-oxazolidinyl) Phosphorus chlorophosphonium chloride (61 mg, 0.24 mmol) was dissolved in 10 mL of dichloromethane, and N,N-diisopropylethylamine (0.11 mL, 0.64 mmol). The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted eluted ((2,5-Difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid Ester 6b (50 mg, white solid), yield: 51.0%.

MS m/z (ESI): 607.9 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((2,5-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-((2,5-Difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Ethyl phenyl)hexane-3-yl)benzimidamide ethyl propionate 6b (48 mg, 0.097 mmol) dissolved in 4 mL of tetrahydrofuran and methanol (V/V = 1:1) in a mixed solvent 1 mL of sodium hydroxide (19.4 mg, 0.49 mmol) was added with stirring and stirred at room temperature for 2 hours. The reaction solution was partially evaporated under reduced pressure, and 5 mL of ethyl acetate and 5 mL of water were added, and 2 drops of 3 M hydrochloric acid were added dropwise to adjust the pH value, and extracted with ethyl acetate (10 mL × 3). The sodium solution (10 mL × 3) was washed with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue obtained was purified by thin layer chromatography (developing solvent: system C) to give 3-(4-(( 2R,3S)/(2S,3R)-1-((2,5-Difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane- 3-yl)benzamide aminopropionic acid 6 (21 mg, white solid), yield: 46.0%.

MS m/z (ESI): 579.8 [M+1]

^{1 H NMR (400MHz, DMSO-} d 6): δ 12.90 (s, 1H), 10.04 (s, 1 H), 8.44 (t, J = 5.1 Hz, 1 H), 7.89 (s, 1 H), 7.79 (s, 1 H), 7.75 (d, J = 8.0 Hz, 2 H), 7.70 (d, J = 8.5 Hz, 2 H), 7.44 (d, J = 8.0 Hz, 2 H), 7.40 (d, J = 8.0 Hz, 2 H), 7.33 (d, J = 8.8 Hz, 1 H), 7.11 (d, J = 8.8 Hz, 1 H), 4.16 (d, J = 11.3 Hz, 1 H), 3.52 - 3.40 (m, 5 H), 2.45 (t, J = 7.0 Hz, 2 H), 1.18 (d, J = 8.0 Hz, 2 H), 0.96 - 0.87 (m, 2 H), 0.67 - 0.61 (m, 3 H)

3-(4-((2R,3S)/(2S,3R)-1-((2,5-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzimidamide)propionic acid 6 was further resolved by supercritical fluid chromatography (SFC) using preparative equipment and chiral column chiral isomers (1 a chiral column ChiralPak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL / min; Mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B for Ethanol)), 3-(4-((2R,3S)-1-((2,5-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)) Alkyl-3-yl)benzhydrylamino)propionic acid 6A (white solid) and 3-(4-((2,5-difluorophenyl)amino)-1-(4-((2,5-difluorophenyl)amino)-1- Oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 6B (white solid).

6A: MS m/z (ESI): 579.8 [M+1]

6B: MS m/z (ESI): 579.8 [M+1]

Example 7

3-(4-((2R,3S)/(2S,3R)-1-((2,4-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzimidamide)propionic acid 7

3-(4-((2R,3S)-1-((2,4-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane -3-yl)benzamide amino)propionic acid 7A

3-(4-((2S,3R)-1-((2,4-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane -3-yl)benzamide amino)propionic acid 7B

first step

3-(4-((2R,3S)/(2S,3R)-1-((2,4-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Ethyl phenyl)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (80 mg, 0.16 mmol), 2,4-difluoroaniline 7a (0.024 mL, 2.4 mmol), bis(2-oxo-3-oxazolidinyl) The phosphinium chloride (61 mg, 0.24 mmol) was dissolved in 20 mL of dichloromethane, and N,N-diisopropylethylamine (0.11 mL, 0.64 mmol). The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted eluted ((2,4-Difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid Ester 7b (40 mg, white solid), yield: 41.2%.

MS m/z (ESI): 607.9 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((2,4-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-((2,4-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Ethyl phenyl)hexane-3-yl)benzimidamide ethyl propionate 7b (40 mg, 0.066 mmol) was dissolved in 6 mL of a mixture solvent of tetrahydrofuran and methanol (V/V = 1:1) 1 mL of sodium hydroxide (14.4 mg, 0.36 mmol) was added with stirring and stirred at room temperature for 1.5 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. Concentration under reduced pressure, the residue obtained was purified by silica gel column chromatography (eluent: System B) to give 3-(4-((2R,3S)/(2S,3R)-1-((2, 4-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 7 (31 mg, White solid), Yield: 81.3%.

MS m/z (ESI): 579.8 [M+1]

¹ H NMR (400 MHz, DMSO-d ₆ ) δ 9.78 (s, 1H), 8.55 (s, 1H), 7.75 (s, 2H), 7.68 (s, 2H), 7.41 (s, 4H), 7.33 ( s, 1H), 7.16 (s, 1H), 6.88 (s, 1H), 4.30 (d, J = 11.4 Hz, 2H), 4.18 – 4.08 (m, 1H), 2.40 (s, 2H), 0.97 – 0.81 (m, 4H), 0.64 (s, 3H).

3-(4-((2R,3S)/(2S,3R)-1-((2,4-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzhydrylamino)propionic acid 7 was further resolved by supercritical fluid chromatography (SFC) using preparative equipment and chiral column chiral isomers (1 a chiral column ChiralPak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL / min; Mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B for Ethanol)), 3-(4-((2R,3S)-1-((2,4-difluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)) Alkyl-3-yl)benzhydrylamino)propionic acid 7A (white solid) and 3-(4-((2S,3R)-1-((2,4-difluorophenyl)amino)-1-) Oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 7B (white solid).

7A: MS m/z (ESI): 579.8 [M+1]

7B: MS m/z (ESI): 579.8 [M+1]

Example 8

3-(4-((2R,3S)/(2S,3R)-1-((3,4-dimethoxyphenyl)amino)-1-oxo-2-(4-(trifluoro)) Oxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 8

3-(4-((2R,3S)-1-((3,4-dimethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)) Hex-3-yl)benzamide amino)propanoic acid 8A

3-(4-((2,4-Dimethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl) Hex-3-yl)benzamide amino)propionic acid 8B

first step

3-(4-((2R,3S)/(2S,3R)-1-((3,4-dimethoxyphenyl)amino)-1-oxo-2-(4-(trifluoro)) Ethyl)phenyl)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (80 mg, 0.16 mmol), 3,4-dimethoxyaniline 8a (25 mg, 0.16 mmol), bis(2-oxo-3-oxazolidine The bisphosphonium chloride (61 mg, 0.24 mmol) was dissolved in 20 mL of methylene chloride. N,N-diisopropylethylamine (0.11 mL, 0.64 mmol). The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted eluted ((3,4-Dimethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzamideamino)propyl Ethyl ester 8b (41 mg, white solid), yield: 40.6%.

MS m/z (ESI): 607.9 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((3,4-dimethoxyphenyl)amino)-1-oxo-2-(4-(trifluoro)) Oxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-((3,4-Dimethoxyphenyl)amino)-1-oxo-2-(4-(trifluoro)) Ethyl methoxy)phenyl)hexane-3-yl)benzimidamide ethyl propionate 8b (41 mg, 0.065 mmol) dissolved in 6 mL of tetrahydrofuran and methanol (V/V = 1:1) In a solvent, 1 mL of sodium hydroxide (14.4 mg, 0.36 mmol) was added with stirring, and the mixture was stirred at room temperature for 1.5 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. Concentration under reduced pressure and the residue obtained was purified by silica gel column chromatography (eluent: System B) to give 3-(4-((2R,3S)/(2S,3R)-1-((3, 4-Dimethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 8 (30 Mg, white solid), Yield: 76.6%.

MS m/z (ESI): 603.9 [M+1]

¹ H NMR (400 MHz, DMSO-d ₆ ) δ 9.90 (s, 1H), 8.55 (s, 1H), 7.75 (d, J = 7.6 Hz, 2H), 7.67 (d, J = 8.5 Hz, 2H) , 7.41 (t, J = 8.6 Hz, 4H), 6.88 (s, 1H), 6.82 (d, J = 8.8 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 4.09 (d, J = 10.9 Hz, 1H), 3.61 (d, J = 8.7 Hz, 6H), 2.41 - 2.34 (m, 2H), 0.88 (ddd, J = 14.7, 12.8, 5.8 Hz, 4H), 0.63 (t, J = 7.0 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-((3,4-dimethoxyphenyl)amino)-1-oxo-2-(4-(trifluoro)) Oxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 8 is further resolved by supercritical fluid chromatography (SFC) using preparative equipment and chiral column chiral isomers ( (1) Chiral Pak AD, 25 x 3 cm, 80 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (2) Whelk O1 (S, S), 25 x 3 cm, 65 mL/ Min; mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL / min; mobile phase A for CO ₂ and B for Ethanol)) To give 3-(4-((2R,3S)-1-((3,4-dimethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)) Phenyl)hexane-3-yl)benzimidamide)propionic acid 8A (white solid) and 3-(4-((2S,3R)-1-((3,4-dimethoxyphenyl) Amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 8B (white solid).

8A: MS m/z (ESI): 603.9 [M+1]

8B: MS m/z (ESI): 603.9 [M+1]

Example 9

3-(4-((2R,3S)/(2S,3R)-1-((4-Trifluoromethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzamide aminopropionic acid 9

3-(4-((2R,3S)-1-((4-Trifluoromethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)) Alkyl-3-yl)benzimidamide)propionic acid 9A

3-(4-((2S,3R)-1-((4-Trifluoromethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)) Alkyl-3-yl)benzamide amino)propionic acid 9B

first step

3-(4-((2R,3S)/(2S,3R)-1-((4-Trifluoromethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Ethyl)phenyl)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (80 mg, 0.16 mmol), 4-trifluoromethoxyaniline 9a (28 mg, 0.16 mmol), bis(2-oxo-3-oxazolidinyl) The phosphinium chloride (61 mg, 0.24 mmol) was dissolved in 20 mL of dichloromethane, and N,N-diisopropylethylamine (0.11 mL, 0.64 mmol) was added and stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted eluted ((4-Trifluoromethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid Ethyl ester 9b (64 mg, white solid), yield: 60.6%.

MS m/z (ESI): 655.8 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((4-Trifluoromethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzamide aminopropionic acid

3-(4-((2R,3S)/(2S,3R)-1-((4-Trifluoromethoxyphenyl)amino)-1-oxo-2-(4-(trifluoro)) Ethyloxy)phenyl)hexane-3-yl)benzamide amino)ethyl propionate 9b (64 mg, 0.097 mmol) in 6 mL of a mixed solvent of tetrahydrofuran and methanol (V/V = 1:1) The solution was added to 1 mL of sodium hydroxide (19.4 mg, 0.49 mmol) with stirring and stirred at room temperature for 1.5 hours. The reaction mixture was concentrated under reduced pressure. EtOAc EtOAc (EtOAc m. Concentration under reduced pressure, and the residue obtained was purified by silica gel column chromatography (eluent: system B) to give 3-(4-((2R,3S)/(2S,3R)-1-((4) -trifluoromethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 9 (27 Mg, white solid), Yield: 44.4%.

MS m/z (ESI): 628.7 [M+1]

¹ H NMR (400 MHz, DMSO-d ₆ ) δ 10.35 (s, 1H), 8.48 (s, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.69 (d, J = 8.5 Hz, 2H) , 7.41 (t, J = 9.1 Hz, 6H), 7.16 (d, J = 8.7 Hz, 2H), 4.17 (d, J = 10.9 Hz, 2H), 2.38 (t, J = 7.2 Hz, 2H), 0.99 – 0.76 (m, 4H), 0.63 (t, J = 7.1 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-((4-Trifluoromethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)pyridin-3-yl)benzimidamide)propionic acid 9 is further resolved by supercritical fluid chromatography (SFC) using preparative equipment and chiral column chiral isomers (( 1) Chiral Pak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL / min Mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B for Ethanol)) To give 3-(4-((2R,3S)-1-((4-trifluoromethoxyphenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl) Hex-3-yl)benzhydrylamino)propionic acid 9A (white solid) and 3-(4-((2S,3R)-1-((4-trifluoromethoxyphenyl)amino)) 1-Oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 9B (white solid).

9A: MS m/z (ESI): 628.7 [M+1]

9B: MS m/z (ESI): 628.7 [M+1]

Example 10

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2,4,6-tri) Fluorophenyl)amino)hexane-3-yl)benzimidamide)propionic acid 10

3-(4-((2R,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2,4,6-trifluorophenyl)amino)) Hex-3-yl)benzamide amino)propionic acid 10A

3-(4-((2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2,4,6-trifluorophenyl)amino)) Hex-3-yl)benzamide amino)propionic acid 10B

first step

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2,4,6-tri) Fluorophenyl)amino)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (80 mg, 0.16 mmol), 2,4,6-trifluoroaniline 10a (35 mg, 0.24 mmol), bis(2-oxo-3-oxazolidine The bisphosphonium chloride (61 mg, 0.24 mmol) was dissolved in 20 mL of methylene chloride. N,N-diisopropylethylamine (0.11 mL, 0.64 mmol). The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted eluted Oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2,4,6-trifluorophenyl)amino)hexane-3-yl)benzylideneamino)propyl Ethyl ester 10b (29 mg, white solid), yield: 29.0%.

MS m/z (ESI): 625.8 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2,4,6-tri) Fluorophenyl)amino)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2,4,6-) Trifluorophenyl)amino)hexane-3-yl)benzhydrylamino)propionic acid ethyl ester 10b (29 mg, 0.05 mmol) dissolved in 6 mL of tetrahydrofuran and methanol (V/V = 1:1) In a solvent, 1 mL of sodium hydroxide (9.3 mg, 0.25 mmol) was added with stirring, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated with EtOAc EtOAc (EtOAc m. The residue was purified by silica gel column chromatography (eluent: system B) to give 3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(3) Fluoromethoxy)phenyl)-1-((2,4,6-trifluorophenyl)amino)hexane-3-yl)benzimidamide)propionic acid 10 (8 mg, white solid) Yield: 26.7%.

MS m/z (ESI): 597.8 [M+1]

_{^{1 H NMR (400MHz, CDCl 3}} ): 1 H NMR (400MHz, DMSO-d 6): δ9.95 (s, 1 H), 8.46 (s, 1 H), 7.76 (d, J = 7.8 Hz, 2 H), 7.68 (d, J = 8.3 Hz, 2 H), 7.41 (t, J = 6.9 Hz, 5 H), 7.22 - 7.12 (m, 1 H), 6.84 (s, 1 H), 4.43 (d , J = 11.3 Hz, 1 H), 2.49 - 2.44 (m, 2 H), 1.34 (d, J = 6.0 Hz, 1 H), 1.22 (s, 6 H), 1.16 (s, 1 H), 0.94 - 0.86 (m, 2 H), 0.62 (t, J = 7.0 Hz, 3 H)

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2,4,6-tri) Fluorophenyl)amino)hexane-3-yl)benzimidamide)propionic acid 10 is further resolved by supercritical fluid chromatography (SFC) using preparative equipment and chiral column chiral isomers ( (1) Chiral Pak AD, 25 x 3 cm, 80 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (2) Whelk O1 (S, S), 25 x 3 cm, 65 mL/ Min; mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL / min; mobile phase A for CO ₂ and B for Ethanol)) To give 3-(4-((2R,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2,4,6-trifluorophenyl) Amino)hexane-3-yl)benzimidamide)propionic acid 10A (white solid) and 3-(4-((2S,3R)-1-oxo-2-(4-(trifluoro)) Oxy)phenyl)-1-((2,4,6-trifluorophenyl)amino)hexane-3-yl)benzylideneamino)propanoic acid 10B (white solid).

10A: MS m/z (ESI): 597.8 [M+1]

10B: MS m/z (ESI): 597.8 [M+1]

Example 11

3-(4-(1-(2-methoxy-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2- Benzomethylene)propionic acid

first step

4-(1-Amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoic acid tert-butyl ester

4-(1-Oxo-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoic acid tert-butyl ester 11a (1.50 g, 3.55 mmol) and titanium under argon Tetraisopropyl acid (2.10 mL, 7.10 mmol) was dissolved in 7N ammonia methanol (20 mL) and allowed to react at room temperature for 18 hours. The reaction solution was cooled to 0 ° C and sodium borohydride (230 mg, 6.03 mmol) was added. The mixture was reacted for 2 hours at room temperature, and a 1 N sodium hydroxide solution was slowly added dropwise to the reaction mixture until no obvious solid precipitated, and the mixture was filtered, and then, the filtrate was concentrated, and then, 20 ml of water was added, and ethyl acetate (10 mL×3) was used for extraction. The combined organic layers were dried over anhydrous sodium sulfate and evaporated, evaporated,lululululululululululululululu Tert-butyl ester oxyphenyl)pentan-2-yl)benzoate 11b (1.02 g, yellow viscous liquid), yield: 68.0%.

¹ H NMR (400 MHz, CDCl ₃ ) δ 7.96 (d, J = 7.4 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 7.7 Hz, 2H), 7.19 (d , J = 7.9 Hz, 2H), 4.07 (d, J = 8.9 Hz, 1H), 2.82 (d, J = 6.4 Hz, 1H), 2.32 (s, 2H), 1.60 (s, 9H), 1.26 (s , 2H), 0.94 (d, J = 6.5 Hz, 2H), 0.75 – 0.58 (m, 3H).

Second step

4-(1-(2-methoxy-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzene Tert-butyl formate

tert-Butyl 4-(1-amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoate 11b (700 mg, 1.65 mmol), 2-methoxy-4 -(trifluoromethyl)benzoic acid 11c (512 mg, 1.50 mmol), bis(2-oxo-3-oxazolidinyl)phosphinium chloride (573 mg, 2.25 mmol) and N,N-diiso Propylethylamine (1.05 mL, 6.00 mmol) was dissolved in 12 mL of dichloromethane and N,N-dimethylformamide (V/V=5/1). The reaction was allowed to react at room temperature. After 18 hours, 20 mL of water was added to the reaction mixture, which was extracted with ethyl acetate (10 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. : System A) purification to give 4-(1-(2-methoxy-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentyl tert-Butyl-2-yl)benzoate 11d (790 mg, pale yellow solid), yield: 86.0%.

MS m/z (ESI): 557.8 [M+1-56]

third step

4-(1-(2-methoxy-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzene Formic acid

4-(1-(2-Methoxy-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl) tert-Butyl benzoate 11d (790 mg, 1.29 mmol) and 85% phosphoric acid (1.20 g, 10.3 mmol) were dissolved in 10 mL of acetonitrile, and the reaction mixture was reacted at 80 ° C for 5 hours. The filtrate was concentrated, and then added with EtOAc (EtOAc) (EtOAc) Fluoromethyl)benzamide amino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 11e (720 mg, pale yellow liquid), yield: 99.0% .

MS m/z (ESI): 557.8 [M+1]

the fourth step

3-(4-(1-(2-methoxy-4-(trifluoromethyl)benzylidinium)-2-(4-(trifluoromethoxy)phenyl)pentan-2- Ethyl benzylamino)propionate

4-(1-(2-Methoxy-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl) Benzoic acid 11e (720 mg, 1.29 mmol), 3-aminopropionic acid ethyl ester hydrochloride (1.0 g, 6.50 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (1.994 mg) , 7.8 mmol) and N,N-diisopropylethylamine (2.20 mL, 1.89 mmol) dissolved in 11 mL of dichloromethane and N,N-dimethylformamide (V/V=9/2) In the mixed solvent, the reaction liquid was reacted at 35 ° C for 38 hours. The reaction solution was concentrated under reduced pressure, and then added with 20 mL of water and ethyl acetate (10 mL×3), and the organic phase was combined with saturated sodium carbonate solution (20 mL×1), 1N hydrochloric acid solution (20 mL×1) and The mixture was washed with brine (20 mL×1) (4-(1-(2-methoxy-4-(trifluoromethyl)benzylidinium)-2-(4-(trifluoromethoxy)phenyl)pentan-2-yl) Benzoguanidinium ethyl propionate 11f (530 mg, white solid), yield: 62.0%.

MS m/z (ESI): 656.8 [M+1]

the fifth step

3-(4-(1-(2-methoxy-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2- Benzomethylene)propionic acid

3-(4-(1-(2-methoxy-4-(trifluoromethyl)benzylidinium)-2-(4-(trifluoromethoxy)phenyl)pentane-2 -Based benzylamino)ethyl propionate 11f (530 mg, 0.81 mmol) and 0.80 mL of lithium hydroxide monohydrate (170 mg, 4.05 mmol) in 10 mL of tetrahydrofuran and methanol (V/V = 1) In the mixed solvent of :1), the reaction liquid was reacted at 30 ° C for 18 hours. The reaction mixture was concentrated under reduced pressure to dryness evaporated. The residue obtained is purified by silica gel column chromatography (eluent: petroleum ether: ethyl acetate) to give 3-(4-(2-methoxy-4-(trifluoromethyl)) Benzylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzylidene amino)propanoic acid 11 (200 mg, white solid), yield: 40.0 %.

MS m/z (ESI): 640.0 [M+1]

¹ H NMR (400 MHz, DMSO) δ 12.20 (s, 1H), 8.52 (d, J = 8.5 Hz, 2H), 7.82 (d, J = 7.9 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.40 (d, J = 7.9 Hz, 2H), 7.35 (d, J = 8.3 Hz, 3H), 7.30 (s, 1H), 7.23 (d, J = 7.7 Hz, 1H), 5.30 (t, J = 8.9 Hz, 1H), 3.76 (s, 3H), 3.47 (d, J = 5.7 Hz, 2H), 3.14 (t, J = 8.3 Hz, 1H), 2.53 (d, J = 6.9 Hz, 2H) , 1.58 (d, J = 9.7 Hz, 1H), 1.15 (s, 1H), 0.98 – 0.84 (m, 2H), 0.65 (t, J = 7.0 Hz, 3H).

Example 12

3-(4-((2R,3S)/(2S,3R)-1-((4-(tert-butyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl) hexane-3-yl)benzamide amino)propionic acid 12

3-(4-((2R,3S)-1-((4-(tert-butyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)) Alkyl-3-yl)benzimidamide)propionic acid 12A

3-(4-((2S,3R)-1-((4-(tert-butyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)) Alkyl-3-yl)benzhydrylamino)propanoic acid 12B

first step

3-(4-((2R,3S)/(2S,3R)-1-((4-(tert-butyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Ethyl)phenyl)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (80 mg, 0.16 mmol), 4-tert-butylaniline 12a (28 mg, 0.19 mmol), 1-hydroxybenzotriazole (1.79 g, 13.3 mmol) and 1-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (40 mg, 0.21 mmol) and N,N-diisopropylethylamine (52 mg, 0.4 mmol) dissolved in 10 It was stirred in mL tetrahydrofuran at room temperature for 24 hours. The reaction mixture was extracted with EtOAc (EtOAc)EtOAc. (eluent: system B) was purified to give 3-(4-((2R,3S)/(2S,3R)-1-((4-(tert-butyl)phenyl)amino)-1-oxo Ethyl 2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoate 12b (32 mg, white solid).

MS m/z (ESI): 626.9 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((4-(tert-butyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzamide aminopropionic acid

3-(4-((2R,3S)/(2S,3R)-1-((4-(tert-butyl)phenyl)amino)-1-oxo-2-(4-(trifluoro)) Ethyloxy)phenyl)hexane-3-yl)benzhydrylamino)propionic acid ethyl ester 12b (32 mg, 0.05 mmol) dissolved in 6 mL of tetrahydrofuran and methanol (V/V = 1:1) Add 1 mL of sodium hydroxide (10 mg, 0.25 mmol) to the solution with stirring and stir at room temperature for 1.5 hours. The reaction mixture was subjected to aq. EtOAc (EtOAc) (EtOAc) The residue was dried over anhydrous sodium sulfate, filtered, and evaporated, evaporated,363363363363363363363363363363363363363363363363 (eluent: system B) was purified to give 3-(4-((2R,3S)/(2S,3R)-1-((4-(tert-butyl)phenyl)amino)-1-oxo 2-(4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 12 (7 mg, white solid).

MS m/z (ESI): 599.9 [M+1]

¹ H NMR (400 MHz, DMSO-d ₆ ) δ 9.86 (s, 1H), 8.47 (s, 1H), 7.74 (d, J = 8.5 Hz, 2H), 7.66 (d, J = 8.6 Hz, 2H) , 7.40 (dd, J = 8.3, 5.1 Hz, 4H), 7.17 (dd, J = 16.5, 9.0 Hz, 6H), 5.33 (d, J = 3.8 Hz, 1H), 4.05 (t, J = 10.0 Hz, 2H), 2.42 – 2.36 (m, 2H), 0.94 - 0.81 (m, 4H), 0.63 (t, J = 7.5 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-((4-(tert-butyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)pyridin-3-yl)benzhydrylamino)propanoic acid 12 is further resolved by supercritical fluid chromatography (SFC) using preparative equipment and chiral column chiral isomers (( 1) Chiral Pak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL / min Mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B for Ethanol)) To give 3-(4-((2R,3S)-1-((4-(tert-butyl)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl) Hex-3-yl)benzhydrylamino)propionic acid 12A (white solid) and 3-(4-((2S,3R)-1-((4-(tert-butyl)phenyl)amino)) 1-Oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 12B (white solid).

12A: MS m/z (ESI): 599.9 [M+1]

12B: MS m/z (ESI): 599.9 [M+1]

Example 13

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((4-(4-(3) Fluoromethyl)-1H-pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzimidamide)propionic acid 13

3-(4-((2R,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((4-(4-(trifluoromethyl))-1H) -pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzimidamide)propionic acid 13A

3-(4-((2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((4-(4-(trifluoromethyl))-1H) -pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzimidamide)propionic acid 13B

first step

1-(4-nitrophenyl)-4-(trifluoromethyl)-1H-pyrazole

1-Fluoro-4-nitrobenzene 13a (1.35 g, 9.55 mmol), 4-(trifluoromethyl)-1H-pyrazole 13b (1 g, 7.35 mmol), potassium carbonate (2.03 g, 14.7 mmol) The reaction solution was reacted at 85 ° C for 7 hours in 10 mL of acetonitrile. The reaction mixture was filtered, and then evaporated tolulujjjjjjjjjjjjjjj %

MS m/z (ESI): 257.9 [M+1]

Second step

4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)aniline

1-(4-Nitrophenyl)-4-(trifluoromethyl)-1H-pyrazole 13c (257 mg, 1 mmol), 10% palladium on carbon (128 mg) was dissolved in 10 mL of methanol. The solution was stirred at room temperature for 5 hours. The reaction solution was filtered, and then evaporated tolulululululululululululululululululululululululululululululululululu

MS m/z (ESI): 227.9 [M+1]

third step

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((4-(4-(3) Fluoromethyl)-1H-pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (90 mg, 0.22 mmol), 4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)aniline 13d (66 mg, 0.29 mmol) , 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (100 mg, 0.26 mmol) and N,N-diisopropyl B The amine (0.12 mL, 0.66 mmol) was dissolved in 5 mL EtOAc EtOAc. The reaction solution was added with 15 mL of water, and extracted with ethyl acetate (8 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. C) Purification to give 3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-(4- (4-(Trifluoromethyl)-1H-pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzimidamide ethyl propionate 13e (155 mg, yellow solid) Yield: 99.9%.

MS m/z (ESI): 704.8 [M+1]

the fourth step

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((4-(4-(3) Fluoromethyl)-1H-pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((4-(4-() Trifluoromethyl)-1H-pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzamide amino)ethyl propionate 13e (155 mg, 0.22 mmol) dissolved in 5 mL of tetrahydrofuran In a mixed solvent of methanol (V/V = 4:1), 0.22 mL of a lithium hydroxide monohydrate (50 mg, 1.1 mmol) was added with stirring, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to remove a solvent, and the mixture was adjusted to pH 2-3 with 1M hydrochloric acid and extracted with ethyl acetate (6 mL×3). The sodium chloride solution (5 mL) was washed with anhydrous sodium sulfate, filtered, and evaporated, evaporated, evaporated, ((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((4-(4-(trifluoromethyl))- 1H-Pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzylideneamino)propanoic acid 13 (8 mg, yellow solid), yield: 5.4%.

MS m/z (ESI): 676.8 [M+1]

¹ H NMR (400 MHz, DMSO) δ 10.14 (s, 1H), 9.00 (s, 1H), 8.43 (s, 1H), 8.11 (s, 1H), 7.76 (d, J = 7.4 Hz, 2H), 7.68 (d, J = 7.8 Hz, 5H), 7.47- 7.38 (m, 6H), 4.09 (d, J = 11.5 Hz, 1H), 3.52 – 3.44 (m, 2H), 3.22 -3.16 (m, 1H) , 2.47- 2.43 (m, 2H), 1.98 - 1.94 (m, 2H), 1.15 - 1.13 (m, 2H), 0.64 (t, J = 6.4 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((4-(4-(3) Fluoromethyl)-1H-pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzimidamide)propionic acid 13 further prepared by using supercritical fluid chromatography (SFC) Separation with chiral column chiral isomers ((1) ChiralPak AD, 25×3 cm, 80 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL / min; Phase A for CO ₂ and B for Ethanol)) was resolved to give 3-(4-((2R,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1 -((4-(4-(Trifluoromethyl)-1H-pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzylideneamino)propanoic acid 13A (white solid) 3-(4-((2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((4-(4-(trifluoromethyl))-1H) -pyrazol-1-yl)phenyl)amino)hexane-3-yl)benzimidamide)propionic acid 13B (white solid).

13A: MS m/z (ESI): 676.8 [M+1]

13B: MS m/z (ESI): 676.8 [M+1]

Example 14

3-(4-((2R,3S)/(2S,3R)-1-((4-(2-methylthiazol-5-yl)phenyl)amino)(1-oxo-2-(4-) (trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 14

3-(4-((2R,3S)-1-((4-(2-methylthiazol-5-yl)phenyl)amino) 1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzimidamide)propionic acid 14A

3-(4-((2S,3R)-1-((4-(2-methylthiazol-5-yl)phenyl)amino) 1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzimidamide)propionic acid 14B

first step

4-(2-methylthiazol-5-yl)aniline

5-Bromo-2-methylthiazole 14a (840 mg, 4.72 mmol), 4-aminophenylboronic acid hydrochloride 14b (900 mg, 5.19 mmol), tetratriphenylphosphine palladium (273 mg, 0.24 mmol) and carbonic acid Sodium (1.90 g, 17.9 mmol) was dissolved in a mixed solvent of 50 mL of toluene, ethanol and water (V/V/V = 2:2:1), the gas was replaced with argon, and the reaction was reacted at 90 ° C for 6 hours. . The reaction mixture was concentrated, EtOAc (EtOAc) (EtOAc) Agent: System C) was purified to give 4-(2-methylthiazol-5-yl)aniline 14c (630 mg, yellow solid), yield: 70.0%

MS m/z (ESI): 190.9 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((4-(2-methylthiazol-5-yl)phenyl)amino)(1-oxo-2-(4-) (trifluoromethoxy)phenyl)hexane-3-yl)benzamide amino)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1m (248 mg, 0.50 mmol), 4-(2-methylthiazol-5-yl)aniline 14c (114 mg, 0.60 mmol), bis (2-oxo- 3-oxazolidinylphosphine chloride (380 mg, 1.00 mmol) and N,N-diisopropylethylamine (0.35 mL, 2.00 mmol) dissolved in 6 mL dichloromethane and N,N-dimethyl In a mixed solvent of carbamide (V/V = 5/1), the reaction solution was allowed to react at room temperature for 18 hours. 20 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and evaporated. Purification to give 3-(4-((2R,3S)/(2S,3R)-1-((4-(2-methylthiazol-5-yl)phenyl)amino) (1-oxo-2) Ethyl 4-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoate 14d (166 mg, off-white solid), yield: 49.7%.

MS m/z (ESI): 667.9 [M+1]

third step

3-(4-((2R,3S)/(2S,3R)-1-((4-(2-methylthiazol-5-yl)phenyl)amino)(1-oxo-2-(4-) (trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-((4-(2-methylthiazol-5-yl)phenyl)amino)(1-oxo-2-(4) -(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide ethyl propionate 14d (166 mg, 0.25 mmol) dissolved in 8 mL of tetrahydrofuran and methanol (V/V = 4: In a mixed solvent of 1), a solution of 0.25 mL of lithium hydroxide monohydrate (53 mg, 1.25 mmol) was added with stirring, and the mixture was stirred at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure to remove a solvent and then adjusted with 1 M hydrochloric acid. The mixture was extracted with ethyl acetate (10 mL×3). Purification by system C) gives 3-(4-((2R,3S)/(2S,3R)-1-((4-(2-methylthiazol-5-yl)phenyl)amino) 1-oxo 2-(4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 14 (100 mg, white solid), yield: 62.0%.

MS m/z (ESI): 639.9 [M+1]

¹ H NMR (400 MHz, DMSO) δ 12.40 – 11.89 (m, 1H), 10.07 (s, 1H), 8.42 (s, 1H), 7.85 (s, 1H), 7.75 (d, J = 8.0 Hz, 2H ), 7.67 (d, J = 8.4 Hz, 2H), 7.38 (dd, J = 21.0, 8.6 Hz, 8H), 4.08 (d, J = 11.0 Hz, 1H), 3.47 (dd, J = 3.4, 2.1 Hz) , 1H), 3.45 – 3.41 (m, 2H), 2.62 (s, 3H), 2.46 (d, J = 7.1 Hz, 2H), 1.38 (dd, J = 10.5, 4.8 Hz, 2H), 0.93 – 0.84 ( m, 2H), 0.64 (t, J = 7.2 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-((4-(2-methylthiazol-5-yl)phenyl)amino)(1-oxo-2-(4-) (Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 14 further by using supercritical fluid chromatography (SFC), using preparative equipment and chiral column chiral isomers Resolution (1) Chiral Pak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3 cm , 65 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B for Ethanol )) For resolution, 3-(4-((2R,3S)-1-((4-(2-methylthiazol-5-yl)phenyl)amino)(1-oxo-2-(4-) (Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 14A (white solid) and 3-(4-((2S,3R)-1-((4-) 2-methylthiazol-5-yl)phenyl)amino(1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 14B (white solid).

14A: MS m/z (ESI): 639.9 [M+1]

14B: MS m/z (ESI): 639.9 [M+1]

Example 15

3-(4-((2R,3S)/(2S,3R)-1-((2-fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4) -(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 15

3-(4-((2R,3S)-1-((2-fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzamide aminopropionic acid 15A

3-(4-((2S,3R)-1-((2-fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl) hexane-3-yl)benzamide amino)propionic acid 15B

first step

3-(4-((2R,3S)/(2S,3R)-1-((2-fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4) -(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl-2-(4-(III) Fluoromethoxy)phenyl)hexanoic acid 1m (200 mg, 0.40 mmol), 2-fluoro-4-(trifluoromethoxy)aniline 15a (116 mg, 0.60 mmol) and N,N-diisopropyl Ethylamine (0.28 mL, 1.60 mmol) was dissolved in 6 mL of dichloromethane, and finally bis(2-oxo-3-oxazolidinyl)phosphinium chloride (152 mg, 0.60 mmol) was added. The reaction was allowed to react for 18 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and then ethyl acetate (60 mL), and then washed with saturated sodium hydrogen carbonate (30 mL×2) and saturated aqueous ammonium chloride (30 mL×2) Drying and concentrating under reduced pressure, the obtained residue was purified by silica gel chromatography (yield: system A) to give 3-(4-((2R,3S)/(2S,3R)-1-(( 2-fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzamide Ethyl propionate 15b (155 mg, white solid), yield: 16.4%.

MS m/z (ESI): 672.8 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((2-fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4) -(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-((2-Fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-() Ethyl 4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamine)propanoate 15b (44 mg, 0.065 mmol) was dissolved in 6 mL of tetrahydrofuran and methanol (V/V=1: In a mixed solvent of 1), a solution of 1.0 mL of sodium hydroxide (13 mg, 0.33 mmol) was added under stirring, and the mixture was stirred at room temperature for 12 hours. The reaction solution was concentrated under reduced pressure to remove a solvent. EtOAc (EtOAc m. Drying, filtration and concentration under reduced pressure, and the obtained residue was purified by silica gel chromatography (developing solvent: system A) to give 3-(4-((2R,3S)/(2S,3R)-1- ((2-Fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzene Amidino)propionic acid 15 (19 mg, white solid), yield: 45.3%.

MS m/z (ESI): 644.7 [M+1]

¹ H NMR (400 MHz, MeOD) δ 7.79 (d, J = 7.9 Hz, 2H), 7.70 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.3 Hz, 1H), 7.33 (d, J = 8.6 Hz, 2H), 7.05 (d, J = 11.6 Hz, 1H), 6.95 (d, J = 7.7 Hz, 1H), 4.12 (d, J = 11.2 Hz, 1H), 3.63 (t, J = 6.6 Hz, 2H), 3.52 – 3.44 (m, 1H), 2.63 (t, J = 6.5 Hz, 2H), 1.06 -0.95 (m, 2H), 0.89 ( Ddd, J = 8.0, 7.1, 4.8 Hz, 2H), 0.73 (t, J = 7.1 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-((2-fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4) -(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 15 further by using supercritical fluid chromatography (SFC), using preparative equipment and chiral columns for heterogeneous heterogeneity Resolution of the body ((1) ChiralPak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3cm, 65 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B for Ethanol)) Resolution to give 3-(4-((2R,3S)-1-((2-fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2- (4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 15A (white solid) and 3-(4-((2S,3R)-1-(( 2-fluoro-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzamide Base) propionic acid 15B (white solid).

15A: MS m/z (ESI): 644.7 [M+1]

15B: MS m/z (ESI): 644.7 [M+1]

Example 16

3-(4-((2R,3S)/(2S,3R)-1-((2-methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-( 4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 16

3-(4-((2R,3S)-1-((2-methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4-(trifluoro)) Oxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 16A

3-(4-((2S,3R)-1-((2-methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4-(trifluoro)) Oxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 16B

first step

3-(4-((2R,3S)/(2S,3R)-1-((2-methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-( 4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl-2-(4-(III) Fluoromethoxy)phenyl)hexanoic acid 1m (200 mg, 0.40 mmol), 2-methyl-4-(trifluoromethoxy)aniline 16a (116 mg, 0.61 mmol) and N,N-diisopropyl Ethylethylamine (0.28 mL, 1.60 mmol) was dissolved in 6 mL of dichloromethane, argon gas was exchanged three times, then bis(2-oxo-3-oxazolidinyl)phosphorus chloride (155 mg, 0.61) was added. (mmol), the reaction solution was allowed to react at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure, and then ethyl acetate (60 mL) was applied, and then saturated sodium hydrogen carbonate solution (30 mL×3) and saturated ammonium chloride solution (30 mL× 3) Washing, drying over anhydrous sodium sulfate, and concentrating under reduced pressure, and the residue obtained is purified by silica gel thin layer chromatography (developing solvent: system A) to give 3-(4-((2R,3S)/(2S, 3R)-1-((2-methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane- Ethyl 3-phenyl)benzamide amino)propanoate 16b (44 mg, white solid), yield: 16.5%.

MS m/z (ESI): 668.9 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((2-methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-( 4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-((2-Methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2- (4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide ethyl propionate 16b (44 mg, 0.066 mmol) dissolved in 6 mL of tetrahydrofuran and methanol (V/V=1) In a mixed solvent of :1), a solution of 1.0 mL of sodium hydroxide (13.2 mg, 0.33 mmol) was added under stirring, and the mixture was stirred at room temperature for 1.5 hours. The reaction mixture was concentrated under reduced pressure and evaporated to dryness. Filtration and concentration under reduced pressure, and the obtained residue was purified by silica gel chromatography (yield: system C) to give 3-(4-((2R,3S)/(2S,3R)-1-(( 2-methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidazole Amino)propionic acid 16 (28 mg, white solid), yield: 66.2%.

MS m/z (ESI): 640.8 [M+1]

¹ H NMR (400 MHz, MeOD) δ 7.83 (d, J = 8.2 Hz, 2H), 7.72 (d, J = 8.6 Hz, 2H), 7.51 (d, J = 8.1 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 6.99 (s, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 8.6 Hz, 1H), 4.03 (d, J = 11.7 Hz, 1H) , 3.66 (t, J = 6.7 Hz, 2H), 3.52 – 3.44 (m, 1H), 2.64 (t, J = 6.4 Hz, 2H), 1.65(s, 3H)1.62 - 1.39 (m, 2H), 1.06 – 0.97 (m, 2H), 0.73 (t, J = 7.3 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-((2-methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-( 4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 16 further by using a supercritical fluid chromatography (SFC) method, using a preparation device and a chiral column The structure is resolved (1) Chiral Pak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 ×3cm, 65 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B For Ethanol)) Resolution was carried out to give 3-(4-((2R,3S)-1-((2-methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo- 2-(4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 16A (white solid) and 3-(4-((2S,3R)-1- ((2-Methyl-4-(trifluoromethoxy)phenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzene Methionine) propionic acid 16B (white solid).

16A: MS m/z (ESI): 640.8 [M+1]

16B: MS m/z (ESI): 640.8 [M+1]

Example 17

3-(4-((2R,3S)/(2S,3R)-1-((4-chloro-2-fluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzamide aminopropionic acid 17

3-(4-((2R,3S)-1-((4-chloro-2-fluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)) Alk-3-yl)benzamide amino)propanoic acid 17A

3-(4-((2S,3R)-1-((4-chloro-2-fluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)) Alkyl-3-yl)benzimidamide)propionic acid 17B

first step

3-(4-((2R,3S)/(2S,3R)-1-((4-chloro-2-fluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Ethyl)phenyl)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl-2-(4-(III) Fluoromethoxy)phenyl)hexanoic acid 1m (100 mg, 0.20 mmol), 4-chloro-2-fluoroaniline 17a (44 mg, 0.30 mmol) and N,N-diisopropylethylamine (0.14 mL, 0.80 mmol) dissolved in 3 mL of dichloromethane, argon gas was exchanged three times, then bis(2-oxo-3-oxazolidinyl)phosphorus chloride (76 mg, 0.30 mmol) was added, and the reaction solution was in the chamber. The reaction mixture was reacted for 5 hours at a temperature. The reaction mixture was concentrated under reduced pressure, and ethyl acetate (60 mL), and then washed with saturated sodium hydrogen carbonate (30 mL×2) and saturated aqueous ammonium chloride (30 mL×2) Drying and concentrating under reduced pressure, the obtained residue was purified by silica gel chromatography (yield: system A) to give 3-(4-((2R,3S)/(2S,3R)-1-(( 4-chloro-2-fluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propionic acid ethyl ester 17b (17 mg, white solid), yield: 13.6%.

MS m/z (ESI): 622.8 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-((4-chloro-2-fluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)hexane-3-yl)benzamide aminopropionic acid

3-(4-((2R,3S)/(2S,3R)-1-((4-Chloro-2-fluorophenyl)amino)-1-oxo-2-(4-(trifluoro)) Ethyl phenyl)hexane-3-yl)benzamide amino)ethyl propionate 17b (36 mg, 0.058 mmol) dissolved in 6 mL of tetrahydrofuran and methanol (V/V = 1:1) To the solution was added 1.0 mL of sodium hydroxide (12.0 mg, 0.29 mmol) with stirring and stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure to remove a solvent, and the mixture was adjusted to pH 3 with 1M hydrochloric acid, and extracted with ethyl acetate (60 mL). The organic phase was washed with saturated aqueous ammonium chloride (30 mL×3) Drying, filtration and concentration under reduced pressure, and the obtained residue was purified by silica gel chromatography (developing solvent: system A) to give 3-(4-((2R,3S)/(2S,3R)-1- ((4-Chloro-2-fluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 17 (19 mg, white solid), yield: 55.1%.

MS m/z (ESI): 594.8 [M+1]

¹ H NMR (400 MHz, MeOD) δ 7.78 (d, J = 8.2 Hz, 2H), 7.70 (d, J = 8.6 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.6 Hz, 1H), 7.33 (d, J = 7.8 Hz, 2H), 7.11 (d, J = 12.7 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 4.11 (d, J = 11.6 Hz, 1H), 3.63 (t, J = 6.9 Hz, 2H), 3.51 – 3.43 (m, 1H), 2.61 (s, 2H), 1.61 – 1.37 (m, 2H), 1.06 – 0.95 (m, 2H) ), 0.72 (t, J = 7.3 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-((4-chloro-2-fluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy) Phenyl)pyridin-3-yl)benzamide aminopropionic acid 17 is further resolved by supercritical fluid chromatography (SFC) using preparative equipment and chiral column chiral isomers (( 1) Chiral Pak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL / min Mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B for Ethanol)) , 3-(4-((2R,3S)-1-((4-chloro-2-fluorophenyl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl) Hex-3-yl)benzhydrylamino)propionic acid 17A (white solid) and 3-(4-((2S,3R)-1-((4-chloro-2-fluorophenyl)amino)) 1-Oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 17B (white solid).

17A: MS m/z (ESI): 594.8 [M+1]

17B: MS m/z (ESI): 594.8 [M+1]

Example 18

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl-1-((6-(trifluoromethyl))) Pyridin-3-yl)amino)hexane-3-yl)benzimidamide)propionic acid 18

3-(4-((2R,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl-1-((6-(trifluoromethyl)pyridin-3-yl)) Amino)hexane-3-yl)benzamide amino)propanoic acid 18A

3-(4-((2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl-1-((6-(trifluoromethyl)pyridin-3-yl)) Amino)hexane-3-yl)benzimidamide)propionic acid 18B

first step

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl-1-((6-(trifluoromethyl))) Pyridin-3-yl)amino)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3S)/(2S,3R))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl-2-(4-(III) Fluoromethoxy)phenyl)hexanoic acid 1m (200 mg, 0.40 mmol), 6-(trifluoromethyl)pyridin-3-amine 18a (98 mg, 0.60 mmol) and N,N-diisopropyl The amine (0.28 mL, 1.60 mmol) was dissolved in 6 mL of dichloromethane, argon gas was dissipated three times, then bis(2-oxo-3-oxazolidinyl)phosphinium chloride (152 mg, 0.60 mmol) was added. The reaction solution was reacted at 35 ° C for 18 hours. The reaction solution was concentrated under reduced pressure, and then ethyl acetate (60 mL) was added, and saturated sodium bicarbonate solution (30 mL×2) and saturated ammonium chloride solution (30 mL×2) The mixture was washed with anhydrous sodium sulfate and evaporated and evaporated.]]]]]]]]]] 3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl-1-((6-(trifluoromethyl)pyridin-3-yl)amino) Ethyl-3-yl)benzhydrylamino)propanoate 18b (34 mg, white solid), yield: 13.3%.

MS m/z (ESI): 639.9 [M+1]

Second step

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl-1-((6-(trifluoromethyl))) Pyridin-3-yl)amino)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl-1-((6-(trifluoromethyl)) Pyridin-3-yl)amino)hexane-3-yl)benzimidamide ethyl propionate 18b (34 mg, 0.053 mmol) dissolved in 6 mL of tetrahydrofuran and methanol (V/V = 1:1) In a mixed solvent, a solution of 1.0 mL of sodium hydroxide (11.0 mg, 0.27 mmol) was added under stirring, and the mixture was stirred at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure to remove a solvent, and then adjusted to pH 3 with 1M hydrochloric acid, The residue was washed with ethyl acetate (30 mL×3) and dried over anhydrous sodium sulfate. Agent: System A) is purified to give 3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl-1-(( 6-(Trifluoromethyl)pyridin-3-yl)amino)hexane-3-yl)benzylideneamino)propanoic acid 18 (8 mg, white solid), yield: 25.0%.

MS m/z (ESI): 694.8 [M+1]

¹ H NMR (400 MHz, DMSO) δ 10.66 (s, 1H), 8.60 (s, 1H), 8.45 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.76 (s, 1H), 7.74 (s, 1H), 7.72 (s, 1H), 7.69 (s, 1H), 7.67 (s, 1H), 7.44 (s, 2H), 7.42 (s, 2H), 4.16 (d, J = 11.8 Hz , 1H), 3.66 (t, J = 6.7 Hz, 2H), 3.52 – 3.44 (m, 1H), 2.46 (t, J = 7.0 Hz, 2H), 1.20 – 1.12 (m, 2H), 0.88 (dd, J = 15.7, 7.0 Hz, 2H), 0.64 (t, J = 7.4 Hz, 3H).

3-(4-((2R,3S)/(2S,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl-1-((6-(trifluoromethyl))) Pyridin-3-yl)amino)hexane-3-yl)benzhydrylamino)propanoic acid 18 is further removed by supercritical fluid chromatography (SFC) using preparative equipment and chiral column chiral isomers (1) Chiral Pak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL/min; mobile phase A for CO ₂ and B for Ethanol)) Resolution was carried out to give 3-(4-((2R,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl-1-((6-(trifluoromethyl)pyridine) 3-yl)amino)hexane-3-yl)benzamide aminopropionic acid 18A (white solid) and 3-(4-((2S,3R)-1-oxo-2-(4-) (Trifluoromethoxy)phenyl-1-((6-(trifluoromethyl)pyridin-3-yl)amino)hexane-3-yl)benzimidamide)propanoic acid 18B (white solid) .

18A: MS m/z (ESI): 694.8 [M+1]

18B: MS m/z (ESI): 694.8 [M+1]

Example 19

3-(4-(1-(4-(Trifluoromethoxy)phenyl)-1-(2',4',6'-trimethyl-[1,1'-biphenyl]-4- Mercaptoamine)pentan-2-yl)benzamide amino)propionic acid

3-(4-((1R,2R)-1-(4-(Trifluoromethoxy)phenyl)-1-(2',4',6'-trimethyl-[1,1'- Biphenyl]-4-ylcarboxamido)pentan-2-yl)benzamide amino)propanoic acid 19A

3-(4-((1S,2S)-1-(4-(Trifluoromethoxy)phenyl)-1-(2',4',6'-trimethyl-[1,1'- Biphenyl]-4-ylcarboxamido)pentan-2-yl)benzamide amino)propanoic acid 19B

first step

4-(1-(4-(Trifluoromethoxy)phenyl)-1-(2',4,6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamide Tert-butyl pentan-2-yl)benzoate

tert-Butyl 4-(1-amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoate 11b (600 mg, 1.42 mmol), 2', 4', 6 '-Trimethyl-[1,1'-biphenyl]-4-carboxylic acid 19a (442 mg, 1.84 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (723 mg) , 2.84 mmol) and N,N-diisopropylethylamine (1.0 mL, 5.68 mmol) dissolved in 12 mL of dichloromethane and N,N-dimethylformamide (V/V=5/1) In a mixed solvent, the reaction mixture was reacted at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure, and then 15 mL of water was applied, and ethyl acetate (10 mL×3), and the organic phase was washed with water (20 mL×2) Drying over sodium sulfate, filtration, EtOAc (EtOAc m.) 1-(2',4,6'-trimethyl-[1,1'-biphenyl]-4-ylcarbamido)pentan-2-yl)benzoic acid tert-butyl ester 19b (820 mg , yellow solid), yield: 89.4%.

MS m/z (ESI): 589.9 [M+1-56]

Second step

4-(1-(4-(Trifluoromethoxy)phenyl)-1-(2',4,6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamide Pentyl-2-yl)benzoic acid

4-(1-(4-(Trifluoromethoxy)phenyl)-1-(2',4,6'-trimethyl-[1,1'-biphenyl]-4-ylformamidine Amino)pentan-2-yl)benzoic acid tert-butyl ester 19b (820 mg, 1.27 mmol) and 85% phosphoric acid (1.20 g, 10.2 mmol) were dissolved in 12 mL of acetonitrile, and the reaction was reacted at 80 ° C. hour. After the reaction mixture was concentrated, EtOAc (EtOAc) (EtOAc (EtOAc) Phenyl)-1-(2',4,6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)pentan-2-yl)benzoic acid 19c ( 750 mg, white solid), yield: 100%.

MS m/z (ESI): 589.9 [M+1]

third step

3-(4-(1-(4-(Trifluoromethoxy)phenyl)-1-(2',4',6'-trimethyl-[1,1'-biphenyl]-4- Ethylamino)pentan-2-yl)benzhydrylamino)propionic acid ethyl ester

4-(1-(4-(Trifluoromethoxy)phenyl)-1-(2',4,6'-trimethyl-[1,1'-biphenyl]-4-ylformamidine Amino)pentan-2-yl)benzoic acid 19c (750 mg, 1.27 mmol), 3-aminopropionic acid ethyl ester hydrochloride (293 mg, 1.91 mmol), 2-(7-azobenzotriazine) Azole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (726 mg, 1.91 mmol) and N,N-diisopropylethylamine (0.90 mL, 5.08 mmol) dissolved in 10 mL In the two N,N-dimethylformamide, the reaction solution was reacted at room temperature for 4 hours. 25 mL of water was added to the reaction mixture, and the mixture was combined with EtOAc (EtOAc m. Purification by gel column chromatography (eluent: system C) to give 3-(4-(1-(trifluoromethoxy)phenyl)-1-(2',4',6'- Trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)pentan-2-yl)benzylideneamino)propionic acid ethyl ester 19d (854 mg, yellow liquid), yield : 97.6%.

MS m/z (ESI): 688.9 [M+1]

the fourth step

3-(4-(1-(4-(Trifluoromethoxy)phenyl)-1-(2',4',6'-trimethyl-[1,1'-biphenyl]-4- Mercaptoamine)pentan-2-yl)benzamide amino)propionic acid

3-(4-(1-(4-(Trifluoromethoxy)phenyl)-1-(2',4',6'-trimethyl-[1,1'-biphenyl]-4 -Methylcarbamimidyl)pentan-2-yl)benzamide amino)propionic acid ethyl ester 19d (854 mg, 1.24 mmol) and 1.20 mL of lithium hydroxide monohydrate (260 mg, 6.20 mmol) solution In a mixed solvent of 12 mL of tetrahydrofuran and methanol (V/V = 1/5), the reaction solution was reacted at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. The residue is purified by silica gel column chromatography (eluent: system C) to give 3-(4-(4-(trifluoromethoxy)phenyl)-1-(2', 4', 6'-Trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)pentan-2-yl)benzamide amino)propanoic acid 19 (750 mg, white solid) Rate: 91.7%.

MS m/z (ESI): 660.9 [M+1]

¹ H NMR (400 MHz, CDCl ₃ ) δ 12.25 (s, 1H), 8.71 (d, J = 8.9 Hz, 1H), 8.45 (t, J = 5.3 Hz, 1H), 7.79 (d, J = 8.2 Hz, 2H), 7.72 (d, J = 8.7 Hz, 2H), 7.53 (dd, J = 13.1, 8.2 Hz, 4H), 7.40 (d, J = 8.1 Hz, 2H), 7.10 (d, J = 8.1 Hz, 2H), 6.90 (s, 2H), 5.33 – 5.25 (m, 1H), 3.42 (dd, J = 12.6, 6.9 Hz, 2H), 3.30 – 3.22 (m, 1H), 2.47 (d, J = 7.2 Hz, 2H), 1.91 (s, 3H), 1.85 (s, 6H), 1.52 (dd, J = 18.6, 7.5 Hz, 1H), 1.09 (dd, J = 16.2, 6.6 Hz, 1H), 0.87 ( Dd, J = 23.8, 10.3 Hz, 2H), 0.63 (t, J = 7.2 Hz, 3H).

3-(4-(1-(4-(Trifluoromethoxy)phenyl)-1-(2',4',6'-trimethyl-[1,1'-biphenyl]-4- Mercaptoamino)pentan-2-yl)benzhydrylamino)propanoic acid 19 is further resolved by supercritical fluid chromatography (SFC) using preparative equipment and chiral column chiral isomers ( Chiral column Whelk O1 (S, S), 300 × 50 mm ID 10 μm, mobile phase A for CO ₂ and B for methanol (0.1% NH ₃ H ₂ O), flow rate 200 mL / min) was resolved to obtain 3- (4-((1R,2R)-1-(4-(Trifluoromethoxy)phenyl)-1-(2',4',6'-trimethyl-[1,1'-biphenyl) ]-4-ylformamido)pentan-2-yl)benzamide amino)propanoic acid 19A (retention time: 4.57 min; ee value: 100%) and 3-(4-((1S, 2S) )-1-(4-(trifluoromethoxy)phenyl)-1-(2',4',6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamide Pentyl-2-yl)benzhydrylamino)propanoic acid 19B (retention time: 10.56 min; ee value: 100%).

19A: MS m/z (ESI): 660.9 [M+1]

19B: MS m/z (ESI): 660.9 [M+1]

Example 20

3-(4-(1-(3,5-Dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)benzamide)-1-(4- (trifluoromethoxy)phenyl)pentan-2-yl)benzamide amino)propionic acid

first step

4-(1-(3,5-Dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)benzimidamide)-1-(4-(trifluoro) Methyl methoxy)phenyl)pentan-2-yl)benzoate

tert-Butyl 4-(1-amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoate 11b (560 mg, 1.32 mmol), 3,5-dimethyl 4-(4-(Trifluoromethyl)-1H-pyrazol-1-yl)benzoic acid 20a (340 mg, 1.20 mmol), bis(2-oxo-3-oxazolidinyl)phosphinium Chlorine (611 mg, 2.40 mmol) and N,N-diisopropylethylamine (0.84 mL, 4.80 mmol) were dissolved in 12 mL dichloromethane and N,N-dimethylformamide (V/V=5) In the mixed solvent of /1), the reaction liquid was reacted at room temperature for 18 hours. The reaction liquid was concentrated under reduced pressure, and then added with 20 mL of water and extracted with ethyl acetate (10 mL×3), and the organic phase was combined with water (15 mL×2) Washed, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: System A) to give 4-(1-(3,5-dimethyl-) 4-(4-(Trifluoromethyl)-1H-pyrazol-1-yl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl) Methyl benzoate 20b (260 mg, white solid), yield: 31.4%.

MS m/z (ESI): 633.8 [M+1-56]

Second step

4-(1-(3,5-Dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)benzimidamide)-1-(4-(trifluoro) Methoxy)phenyl)pentan-2-yl)benzoic acid

4-(1-(3,5-Dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)benzimidamide)-1-(4-(III) Methyl fluoromethoxy)phenyl)pentan-2-yl)benzoate 20b (260 mg, 0.38 mmol) and 85% phosphoric acid (350 mg, 3.00 mmol) were dissolved in 8 mL acetonitrile at 80 ° C The reaction was carried out for 4 hours. After the reaction mixture was concentrated, EtOAc (EtOAc) (EtOAc m. 4-(4-(Trifluoromethyl)-1H-pyrazol-1-yl)benzylideneamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl ) benzoic acid 20c (240 mg, pale yellow liquid), yield: 100%.

MS m/z (ESI): 633.8 [M+1]

third step

3-(4-(1-(3,5-Dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)benzamide)-1-(4- (trifluoromethoxy)phenyl)pentan-2-yl)benzamide amino)propionic acid ethyl ester

4-(1-(3,5-Dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)benzimidamide)-1-(4-(III) Fluoromethoxy)phenyl)pentan-2-yl)benzoic acid 20c (240 mg, 0.38 mmol), 3-aminopropionic acid ethyl ester hydrochloride (117 mg, 0.76 mmol), 2-(7-even) Nitrobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (217 mg, 0.57 mmol) and N,N-diisopropylethylamine (0.30 mL, 1.52 mmol) Dissolved in 5 mL of di-N,N-dimethylformamide, and the reaction was allowed to react at room temperature for 4 hours. To the reaction mixture, 25 mL of water was added, and the mixture was evaporated. Purification by gel column chromatography (eluent: system C) to give 3-(4-(1-(3,5-dimethyl-4-(4-(trifluoromethyl)-1H-pyrazole) -1-yl)benzamide amino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzylidene amino)propionic acid ethyl ester 20d (278 mg, class White solid), Yield: 100%.

MS m/z (ESI): 732.9 [M+1]

the fourth step

3-(4-(1-(3,5-Dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)benzamide)-1-(4- (trifluoromethoxy)phenyl)pentan-2-yl)benzamide amino)propionic acid

3-(4-(1-(3,5-Dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)benzamide)-1-(4) -(Trifluoromethoxy)phenyl)pentan-2-yl)benzylideneamine)ethyl propionate 20d (278 mg, 0.38 mmol) and 0.40 mL of lithium hydroxide monohydrate (80 mg, 1.90 mmol) The solution was dissolved in a mixed solvent of 6 mL of tetrahydrofuran and methanol (V/V = 1/2), and the reaction solution was reacted at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. The residue was purified by silica gel column chromatography (eluent: system C) to give 3-(4-(1,3-(3)-dimethyl-4-(4-trifluoromethyl)-1H- Pyrazol-1-yl)benzamide amino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide aminopropionic acid 20 (197 mg, white Solid), Yield: 73.8%.

MS m/z (ESI): 704.9 [M+1]

¹ H NMR (400 MHz, DMSO) δ 12.25 (s, 1H), 9.10 (d, J = 8.7 Hz, 1H), 8.50 (t, J = 5.3 Hz, 1H), 8.07 (s, 1H), 7.69 ( d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.1 Hz, 2H), 7.14 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 7.4 Hz, 1H), 6.83 (d, J = 7.2 Hz, 1H), 5.17 – 5.06 (m, 1H), 3.58 – 3.49 (m, 2H), 3.12 – 3.02 (m, 1H), 2.59 (t, J = 6.9 Hz, 2H), 1.41 (s, 3H), 1.23 (s, 3H), 1.22 – 1.15 (m, 1H), 1.03 – 0.91 (m, 1H), 0.76 (dd, J = 14.6, 7.7 Hz, 2H), 0.55 (t, J = 7.1 Hz, 3H).

Example 21

3-(4-(1-(4-Cyanobenzoguanamine)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide)propionic acid

first step

Tert-butyl 4-(1-(4-cyanobenzamide)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoate

4-(1-Amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoic acid tert-butyl ester 11b (423 mg, 1.00 mmol), 4-cyanobenzoic acid 21a (162 mg, 1.10 mmol), bis(2-oxo-3-oxazolidinyl)phosphinium chloride (510 mg, 2.00 mmol) and N,N-diisopropylethylamine (0.70 mL, 4.00 mmol) It is dissolved in a mixed solvent of 12 mL of dichloromethane and N,N-dimethylformamide (V/V=5/1), and the reaction solution is reacted at room temperature for 18 hours. 20 mL of ethyl acetate and 20 mL of water, EtOAc, EtOAc (EtOAc)EtOAc. The residue obtained is purified by silica gel column chromatography (eluent: System A) to give 4-(1-(4-cyanobenzamide)-1-(4-(trifluoromethoxy) Phenyl)pentan-2-yl)benzoic acid tert-butyl ester 21b (406 mg, white solid), yield: 73.5%.

MS m/z (ESI): 496.9 [M+1-56]

Second step

4-(1-(4-Cyanobenzamide)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid

tert-Butyl 4-(1-(4-cyanobenzamide)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoate 21b (406 mg, 0.73 mmol) was dissolved in 3 mL of dichloromethane, 3 mL of trifluoroacetic acid was added, and the reaction was allowed to react at room temperature for 18 hours. After the reaction mixture was concentrated, EtOAc EtOAc (EtOAc m. 1-(4-(Trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 21c (337 mg, white solid), yield: 93.0%.

MS m/z (ESI): 496.9 [M+1]

third step

3-(4-(1-(4-Cyanobenzoguanamine)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide)propionic acid Ethyl ester

4-(1-(4-Cyanobenzamide)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 21c (337 mg, 0.68 mmol) , 3-aminopropionic acid ethyl ester hydrochloride (261 mg, 1.70 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (432 mg, 1.70 mmol) and N,N-di Isopropylethylamine (0.56 mL, 3.39 mmol) was dissolved in 9 mL of dichloromethane, and the reaction was allowed to react at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure. EtOAc (EtOAc)EtOAc. Purification by column chromatography (eluent: System A) to give 3-(4-(1-(4-cyanobenzamide)-1-(4-(trifluoromethoxy)phenyl) Ethylpentane-2-yl)benzhydrylamino)propanoate 21d (51 mg, off-white solid), yield: 12.6%.

MS m/z (ESI): 595.9 [M+1]

the fourth step

3-(4-(1-(4-Cyanobenzoguanamine)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide)propionic acid

3-(4-(1-(4-Cyanobenzoguanamine)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide) Ethyl ester 21d (51 mg, 0.086 mmol) and 1.0 mL of lithium hydroxide monohydrate (18 mg, 0.428 mmol) were dissolved in a mixture of 5 mL of tetrahydrofuran and methanol (V/V = 1/4). The reaction was carried out at room temperature for 18 hours. 30 mL of ethyl acetate was added to the reaction mixture, and the mixture was adjusted to pH with 1M hydrochloric acid, and the mixture was acidified, and the aqueous phase was extracted with ethyl acetate (20 mL). The combined organic phase was washed with water (20 mL×2) Drying over sodium sulfate, filtration and concentration under reduced pressure, the obtained residue was purified by silica gel chromatography (yield: system C) to give 3-(4-(4- cyanobenzamide) 1-(4-(Trifluoromethoxy)phenyl)pentan-2-yl)benzylideneamino)propanoic acid 21 (17 mg, white solid), yield: 34.8%.

MS m/z (ESI): 567.9 [M+1]

¹ H NMR (400 MHz, DMSO) δ 8.92 (d, J = 9.1 Hz, 1H), 8.50 (s, 1H), 7.85 (d, J = 8.5 Hz, 2H), 7.76 (d, J = 7.9 Hz, 2H), 7.71 (d, J = 8.6 Hz, 2H), 7.62 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.40 (d, J = 8.2 Hz, 2H) , 5.28 (d, J = 1.8 Hz, 1H), 3.43 – 3.38 (m, 2H), 2.47 – 2.42 (m, 2H), 1.62 – 1.45 (m, 2H), 1.16 – 1.00 (m, 2H), 0.62 (t, J = 7.2 Hz, 3H).

Example 22

3-(4-(1-(3,5-dimethylbenzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide Propionic acid

first step

tert-Butyl 4-(1-(3,5-dimethylbenzylidenyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoate

tert-Butyl 4-(1-amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoate 11b (423 mg, 1.00 mmol), 3,5-dimethylbenzene Formic acid 22a (165 mg, 1.10 mmol), bis(2-oxo-3-oxazolidinyl)phosphinium chloride (510 mg, 2.00 mmol) and N,N-diisopropylethylamine (0.70 mL, 4.00 mmol) was dissolved in a mixed solvent of 12 mL of dichloromethane and N,N-dimethylformamide (V/V = 5/1), and the reaction was allowed to react at room temperature for 18 hours. After adding 20 mL of ethyl acetate and 20 mL of water, the layers were separated, the aqueous phase was extracted with ethyl acetate (20 mL×2), and the organic phase was washed with water (10 mL×3), dried over anhydrous sodium sulfate Concentration, the residue obtained is purified by silica gel column chromatography (eluent: System A) to give 4-(1-(3,5-dimethylbenzylamino)amino-1-(4-( tert-Butyl trifluoromethoxy)phenyl)pentan-2-yl)benzoate 22b (389 mg, white solid), yield: 70.0%.

MS m/z (ESI): 557.0 [M+1]

Second step

4-(1-(3,5-Dimethylbenzylidinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid

tert-Butyl 4-(1-(3,5-dimethylbenzylideneamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoate 22b ( 260 mg, 0.38 mmol) was dissolved in 3 mL of dichloromethane, 3 mL of trifluoroacetic acid was added, and the reaction was allowed to react at room temperature for 18 hours. After the reaction mixture was concentrated, EtOAc EtOAc (EtOAc m. Methionamine)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 22c (327 mg, white liquid), yield: 93.5%.

MS m/z (ESI): 499.9 [M+1]

third step

3-(4-(1-(3,5-dimethylbenzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide Ethyl propionate

4-(1-(3,5-dimethylbenzylideneamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 22c (327 mg, 0.65 mmol), 3-aminopropionic acid ethyl ester hydrochloride (251 mg, 1.64 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (417 mg, 1.64 mmol) and N, N-Diisopropylethylamine (0.54 mL, 3.27 mmol) was dissolved in 5 mL of N,N-dimethylformamide, and the reaction was allowed to react at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure. EtOAc (EtOAc)EtOAc. Purification by column chromatography (eluent: system C) gave 3-(4-(1-(3,5-dimethylbenzylamino)amino-1-(4-trifluoromethoxy) Phenyl)pentan-2-yl)benzhydrylamino)propionic acid ethyl ester 22d (128 mg, white solid), yield: 32.8%.

MS m/z (ESI): 598.9 [M+1]

the fourth step

3-(4-(1-(3,5-dimethylbenzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide Propionic acid

3-(4-(1-(3,5-dimethylbenzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide Ethyl propionate 22d (128 mg, 0.31 mmol) and 1.0 mL of lithium hydroxide monohydrate (72 mg, 1.71 mmol) were dissolved in a mixture of 5 mL of tetrahydrofuran and methanol (V/V = 1/4). The reaction solution was reacted at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure. EtOAc (EtOAc) (EtOAc m. Washed with 30 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give 3-(4-(1-(3,5-dimethylbenzylamino)amino-1-(4-(3) Fluoromethoxy)phenyl)pentan-2-yl)benzhydrylamino)propanoic acid 22 (98 mg, white solid), yield: 81.8%.

MS m/z (ESI): 570.9 [M+1]

¹ H NMR (400 MHz, DMSO) δ 8.50 (s, 1H), 8.46 (d, J = 10.0 Hz, 1H), 7.78 (d, J = 7.8 Hz, 2H), 7.70 (d, J = 8.6 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 7.03 (s, 1H), 6.99 (s, 2H), 5.21 (d, J = 10.1 Hz, 1H), 3.46 – 3.38 (m, 2H), 2.47 (d, J = 2.4 Hz, 2H), 2.20 (s, 6H), 1.59 – 1.46 (m, 2H), 1.14 – 0.99 (m, 2H), 0.63 (t, J = 7.3 Hz, 3H).

Example 23

3-(4-(1-(5-Chloropyridinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzylideneamino)propanoic acid

first step

Tert-butyl 4-(1-(5-chloropyridinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoate

4-(1-Amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoic acid tert-butyl ester 11b (423 mg, 1.00 mmol), 5-chloropicolinic acid 23a ( 175 mg, 1.10 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (510 mg, 2.00 mmol) and N,N-diisopropylethylamine (0.70 mL, 4.00 mmol) Dissolved in a mixed solvent of 10 mL of dichloromethane and N,N-dimethylformamide (V/V=4/1), the reaction solution was reacted at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure and then added to 20 The mixture was extracted with ethyl acetate (10 mL×3). EtOAc m. Eluent: System A) was purified to give 4-(1-(5-chloropyridinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid Butyl ester 23b (470 mg, pale yellow solid), yield: 83.5%.

MS m/z (ESI): 584.8 [M+23]

Second step

4-(1-(5-Chloropyridinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid

tert-Butyl 4-(1-(5-chloropyridinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoate 23b (470 mg, 0.83 mmol Dissolved in 6 mL of dichloromethane, 6 mL of trifluoroacetic acid was added, and the reaction solution was reacted at 25 ° C for 2 hours. After the reaction mixture was concentrated, EtOAc (EtOAc) (EtOAc (EtOAc) (5-Chloropyridinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 23c (423 mg, yellow liquid), yield: 100%.

MS m/z (ESI): 506.8 [M+1]

third step

Ethyl 3-(4-(1-(5-chloropyridinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzylideneamino)propanoate

4-(1-(5-Chloropyridinylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 23c (423 mg, 0.83 mmol), 3 -Aminopropionic acid ethyl ester hydrochloride (255 mg, 1.66 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluron hexafluorophosphate ( 473 mg, 1.24 mmol) and N,N-diisopropylethylamine (0.60 mL, 3.32 mmol) were dissolved in 8 mL of N,N-dimethylformamide, and the reaction was reacted at 25 ° C for 3 hours. . To the reaction mixture, 30 ml of water was added, and the mixture was evaporated to ethyl acetate (10 mL × 3). Purification by gel column chromatography (eluent: system D) to give 3-(4-(5-chloropyridinyl)-1-(4-(trifluoromethoxy)phenyl)pentane Ethyl-2-yl)benzhydrylamino)propanoate 23d (340 mg, white solid), yield: 67.6%.

MS m/z (ESI): 605.8 [M+1]

the fourth step

3-(4-(1-(5-Chloropyridinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzylideneamino)propanoic acid

3-(4-(1-(5-Chloropyridinylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide)propionic acid Ester 23d (340 mg, 0.56 mmol) and 0.50 mL of lithium hydroxide monohydrate (120 mg, 2.80 mmol) were dissolved in 8 mL of tetrahydrofuran and methanol (V/V = 1/4) in a mixed solvent. The reaction was carried out for 18 hours under temperature. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. Purification by chromatography (eluent: system C) gave 3-(4-(5-chloropyridinium)-1-(4-(trifluoromethoxy)phenyl)pentane- 2-yl)benzamide aminopropionic acid 23 (290 mg, white solid), yield: 89.5%.

MS m/z (ESI): 577.8 [M+1]

¹ H NMR (400 MHz, DMSO) δ 12.18 (s, 1H), 9.11 (d, J = 9.2 Hz, 1H), 8.60 (d, J = 2.1 Hz, 1H), 8.43 (t, J = 5.4 Hz, 1H), 8.00 (dd, J = 8.5, 2.1 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.73 (t, J = 8.7 Hz, 4H), 7.46 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.2 Hz, 2H), 5.29 (t, J = 10.0 Hz, 1H), 3.50 – 3.37 (m, 3H), 2.47 (d, J = 7.0 Hz, 2H), 1.52 ( d, J = 11.5 Hz, 1H), 1.15 – 1.04 (m, 1H), 0.86 (dd, J = 15.7, 9.5 Hz, 2H), 0.63 (t, J = 7.2 Hz, 3H).

Example 24

3-(4-(1-(4-Chloro-2-methylbenzylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide Propionate

first step

4-(1-(4-Chloro-2-methylbenzylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid tert-butyl ester

tert-Butyl 4-(1-amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoate 11b (423 mg, 1.00 mmol), 4-chloro-2methyl Benzoic acid 24a (190 mg, 1.10 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (510 mg, 2.00 mmol) and N,N-diisopropylethylamine (0.70 mL) , 4.00 mmol) was dissolved in a mixed solvent of 10 mL of dichloromethane and N,N-dimethylformamide (V/V=4/1), and the reaction solution was reacted at room temperature for 18 hours. After concentrating, 20 mL of water was added, and the mixture was extracted with ethyl acetate (10 mL×3). The organic phase was washed with water (30 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Chromatography (eluent: System A) to give 4-(1-(4-chloro-2-methylbenzylamino)-1-(4-(trifluoromethoxy)phenyl) tert-Butyl-2-pentyl benzoate 24b (460 mg, white solid), yield: 79.9%.

MS m/z (ESI): 597.8 [M+23]

Second step

4-(1-(4-Chloro-2-methylbenzamide)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid

4-(1-(4-Chloro-2-methylbenzamide)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid tert-butyl ester 24b (460 mg, 0.80 mmol) and 85% phosphoric acid (553 mg, 4.80 mmol) were dissolved in 5 mL of acetonitrile, and the reaction was reacted at 80 ° C for 4 hours. After the reaction mixture was concentrated, EtOAc (EtOAc) (EtOAc) Benzobenzylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 24c (416 mg, yellow liquid), yield: 100%.

MS m/z (ESI): 519.8 [M+1]

third step

3-(4-(1-(4-Chloro-2-methylbenzylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide Ethyl propionate

4-(1-(4-Chloro-2-methylbenzylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 24c (416 mg , 0.85 mmol), 3-aminopropionic acid ethyl ester hydrochloride (250 mg, 1.60 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyl Urea hexafluorophosphate (456 mg, 1.20 mmol) and N,N-diisopropylethylamine (0.60 mL, 3.20 mmol) were dissolved in 8 mL of N,N-dimethylformamide. The reaction was carried out at 25 ° C for 3 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. -(4-(1-(4-chloro-2-methylbenzamide)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzimidamide Ethyl propionate 24d (495 mg, white solid), yield: 100%.

MS m/z (ESI): 618.90 [M+1]

the fourth step

3-(4-(1-(4-Chloro-2-methylbenzylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamide Propionate

3-(4-(1-(4-Chloro-2-methylbenzylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzimidazole Ethyl)ethyl propionate 24d (495 mg, 0.80 mmol) and 0.80 mL of lithium hydroxide monohydrate (170 mg, 4.00 mmol) in 9 mL of a mixed solvent of tetrahydrofuran and methanol (V/V = 2/7) The reaction solution was reacted at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. Purification by chromatography (eluent: System C) to give 3-(4-(1-chloro-methyl-2-methylbenzamide)-1-(4-(trifluoromethoxy) Phenyl)pentan-2-yl)benzhydrylamino)propanoic acid 24 (270 mg, white solid), yield: 57.1%.

MS m/z (ESI): 590.8 [M+1]

¹ H NMR (400 MHz, DMSO) δ 12.17 (s, 1H), 8.67 (d, J = 9.4 Hz, 1H), 8.49 (t, J = 5.1 Hz, 1H), 7.81 (d, J = 8.0 Hz, 2H), 7.66 (d, J = 8.3 Hz, 2H), 7.42 (dd, J = 11.2, 8.5 Hz, 4H), 7.19 (s, 1H), 7.15 (d, J = 7.8 Hz, 1H), 6.70 ( d, J = 8.4 Hz, 1H), 5.29 (t, J = 10.1 Hz, 1H), 3.46 (dd, J = 11.9, 6.0 Hz, 2H), 3.03 (td, J = 9.8, 1.3 Hz, 1H), 2.69 (s, 3H), 2.53 (d, J = 7.6 Hz, 2H), 1.52 (dd, J = 18.9, 6.0 Hz, 1H), 1.12 – 1.02 (m, 1H), 0.90 – 0.77 (m, 2H) , 0.61 (t, J = 7.0 Hz, 3H).

Example 25

3-(4-(1-(2-Fluoro-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl) Benzylamino)propionic acid

first step

4-(1-(2-Fluoro-4-(trifluoromethyl)benzylideneamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid Butyl ester

tert-Butyl 4-(1-amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoate 11b (423 mg, 1.00 mmol), 2-fluoro-4-( Trifluoromethyl)benzoic acid 25a (230 mg, 1.10 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (510 mg, 2.00 mmol) and N,N-diisopropyl Ethylamine (0.70 mL, 4.00 mmol) was dissolved in 10 mL of dichloromethane and N,N-dimethylformamide (V/V=4/1), and the reaction was allowed to react at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. The residue was purified by silica gel column chromatography (eluent: System A) to give 4-(1-(2-fluoro-4-(trifluoromethyl) benzhydryl)-1-(4-( tert-Butyl trifluoromethoxy)phenyl)pentan-2-yl)benzoate 25b (500 mg, white solid), yield: 81.6%.

MS m/z (ESI): 557.8 [M+1-56]

Second step

4-(1-(2-Fluoro-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid

4-(1-(2-Fluoro-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid tert-Butyl ester 25b (500 mg, 0.82 mmol) and 85% phosphoric acid (753 mg, 6.53 mmol) were dissolved in 10 mL of acetonitrile, and the reaction mixture was reacted at 80 ° C for 4 hours. After the reaction mixture was concentrated, EtOAc (EtOAc m. Trifluoromethyl)benzylideneamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 25c (457 mg, yellow solid), yield: 100% .

MS m/z (ESI): 557.8 [M+1]

third step

3-(4-(1-(2-Fluoro-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl) Benzylamino) tert-butyl propionate

4-(1-(2-Fluoro-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 25c (457 mg, 0.82 mmol), tert-butyl 3-aminopropionate hydrochloride (300 mg, 1.64 mmol), 2-(7-azobenzotriazole)-N,N,N',N '-Tetramethylurea hexafluorophosphate (470 mg, 1.23 mmol) and N,N-diisopropylethylamine (0.60 mL, 3.28 mmol) dissolved in 8 mL of N,N-dimethylformamide The reaction solution was reacted at 25 ° C for 3 hours. After adding 30 mL of water to the reaction mixture, ethyl acetate (15 mL × 3) was evaporated. 4-(1-(2-Fluoro-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzimidazole Amino) tert-butyl propionate 25d (560 mg, yellow solid), yield: 100%.

MS m/z (ESI): 571.90 [M+1]

the fourth step

3-(4-(1-(2-Fluoro-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl) Benzylamino)propionic acid

3-(4-(1-(2-Fluoro-4-(trifluoromethyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl Benzylguanidino) tert-butyl propionate 25d (560 mg, 0.82 mmol) and 85% phosphoric acid (570 mg, 4.92 mmol) were dissolved in 20 mL of acetonitrile, and the reaction was reacted at 80 ° C for 4 hours. The reaction solution had a large amount of solid precipitated, and the filter cake was washed with water (15 mL×2) and dichloromethane (15 mL×2), and the filter cake was dissolved in 20 mL of methanol and toluene (V/V=3/1). The mixture was concentrated to dryness under reduced pressure and dried in vacuo to give 3-(4-(1-(2-fluoro-4-(trifluoromethyl) benzhydryl)-1-(4-(3) Fluoromethoxy)phenyl)pentan-2-yl)benzhydrylamino)propanoic acid 25 (340 mg, white solid), yield: 66.0%.

MS m/z (ESI): 628.8 [M+1]

¹ H NMR (400 MHz, DMSO) δ 12.06 (d, J = 3.7 Hz, 1H), 8.89 (d, J = 8.9 Hz, 1H), 8.50 (t, J = 5.5 Hz, 1H), 7.80 (d, J = 8.1 Hz, 2H), 7.70 (d, J = 9.4 Hz, 1H), 7.64 (d, J = 8.6 Hz, 2H), 7.53 (d, J = 8.0 Hz, 1H), 7.48 – 7.34 (m, 4H), 7.15 (t, J = 7.3 Hz, 1H), 5.31 (t, J = 9.8 Hz, 1H), 3.46 (dd, J = 12.6, 6.7 Hz, 2H), 3.08 (td, J = 10.9, 2.5 Hz, 1H), 2.57 – 2.52 (m, 2H), 1.64 – 1.48 (m, 1H), 1.18 – 1.05 (m, 1H), 0.97 – 0.77 (m, 2H), 0.62 (t, J = 7.2 Hz, 3H).

Example 26

3-(4-(1-(Iso-indolyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzimidamide)propionic acid

first step

Tert-butyl 4-(1-(isonazinamide)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoate

tert-Butyl 4-(1-amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoate 11b (423 mg, 1.00 mmol), isonicotinic acid 26a (150 mg , 1.20 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (510 mg, 2.00 mmol) and N,N-diisopropylethylamine (0.70 mL, 4.00 mmol) 11 mL of dichloromethane and N,N-dimethylformamide (V/V=8/3) in a mixed solvent, the reaction solution was allowed to react at room temperature for 18 hours. The reaction solution was concentrated under reduced pressure and then added with 20 mL of water. The organic phase was washed with water (30 mL×3), dried over anhydrous sodium sulfate, filtered and evaporated. Agent: System A) was purified to give 4-(1-(isonohhenamidino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid tert-butyl ester 26b ( 450 mg, yellow solid), yield: 85.2%.

MS m/z (ESI): 528.9 [M+1]

Second step

4-(1-(Isoindolyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid

4-(1-(Isoindolinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid tert-butyl ester 26b (450 mg, 0.85 mmol) 4 mL of trifluoroacetic acid was dissolved in 4 mL of dichloromethane, and the reaction solution was reacted at 25 ° C for 2 hours. After the reaction mixture was concentrated, EtOAc (EtOAc) (EtOAc (EtOAc) Isonicotinosyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 26c (400 mg, yellow solid), yield: 100%.

MS m/z (ESI): 472.9 [M+1]

third step

3-(4-(1-(Isoindolinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzylideneamino)propionic acid ethyl ester

4-(1-(Isoindolinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 26c (400 mg, 0.85 mmol), 3-amino Ethyl propionate hydrochloride (261 mg, 1.70 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (485 mg 1.28 mmol) and N,N-diisopropylethylamine (0.60 mL, 3.40 mmol) were dissolved in 8 mL of N,N-dimethylformamide, and the reaction mixture was reacted at 25 ° C for 4 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. -(4-(1-(Isoindolinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzylideneamine)ethyl propionate 26d (485 Mg, white solid), yield: 100%.

MS m/z (ESI): 571.90 [M+1]

the fourth step

3-(4-(1-(Iso-indolyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzimidamide)propionic acid

3-(4-(1-(Isoindolinyl)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzylideneamine)ethyl propionate 26d (485 mg, 0.85 mmol) and 0.80 mL of lithium hydroxide monohydrate (180 mg, 4.25 mmol) in 12 mL of tetrahydrofuran and methanol (V/V = 1/5) in a mixed solvent at 25 ° C Reaction for 4 hours. The reaction solution was concentrated under reduced pressure, and the mixture was adjusted to pH 2-3 with 1M hydrochloric acid, and a large amount of solids was precipitated, filtered, and the filter cake was washed with water (15 mL×2) and dichloromethane (15 mL×2), and filtered. The cake was dissolved in 20 mL of a mixture of methanol and toluene (V/V = 3/1), concentrated to dryness under reduced pressure and dried in vacuo to give 3-(4-(1-(isoindolyl)-1- (4-(Trifluoromethoxy)phenyl)pentan-2-yl)benzhydrylamino)propanoic acid 26 (350 mg, white solid), yield: 75.8%.

MS m/z (ESI): 543.8 [M+1]

¹ H NMR (400 MHz, DMSO) δ 12.26 (s, 1H), 8.95 (d, J = 8.3 Hz, 1H), 8.62 (d, J = 5.5 Hz, 2H), 8.46 (t, J = 5.1 Hz, 1H), 7.77 (d, J = 7.9 Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 7.40 (t, J = 5.8 Hz, 4H) , 5.32 – 5.22 (m, 1H), 3.42 (dd, J = 12.1, 5.9 Hz, 2H), 3.21 (t, J = 11.2 Hz, 1H), 2.46 (d, J = 4.5 Hz, 2H), 1.55 ( Dd, J = 20.5, 8.8 Hz, 1H), 1.08 (dd, J = 19.2, 7.6 Hz, 1H), 0.88 (dt, J = 15.7, 6.5 Hz, 2H), 0.63 (t, J = 7.2 Hz, 3H ).

Example 27

3-(4-(1-(tert-butyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamideamino)propanoic acid 27

first step

Tert-butyl 4-(1-(tert-butyl)benzylideneamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoate

tert-Butyl 4-(1-amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoate 11b (423 mg, 1.00 mmol), 4-(tert-butyl) Benzoic acid 27a (215 mg, 1.20 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (510 mg, 2.00 mmol) and N,N-diisopropylethylamine (0.70 mL) , 4.00 mmol) was dissolved in a mixed solvent of 10 mL of dichloromethane and N,N-dimethylformamide (V/V=4/1), and the reaction solution was reacted at room temperature for 18 hours. After concentrating, 20 mL of water was added, and the mixture was extracted with ethyl acetate (10 mL×3). The organic phase was washed with water (30 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Chromatography (eluent: System A) to give 4-(1-(tert-butyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentane-2 tert-Butyl benzoate 27b (260 mg, yellow solid), yield: 68.6%.

MS m/z (ESI): 527.9 [M+1-56]

Second step

4-(1-(tert-butyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid

tert-Butyl 4-(1-(tert-butyl)benzylamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoate 27b (400 mg, 0.68 mmol) and 4 mL of trifluoroacetic acid were dissolved in 4 mL of dichloromethane, and the reaction solution was reacted at 25 ° C for 2 hours. After the reaction mixture was concentrated, EtOAc (3 mL, EtOAc) (tert-Butyl)benzylideneamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 27c (362 mg, yellow liquid), yield: 100% .

MS m/z (ESI): 527.9 [M+1]

third step

3-(4-(1-(tert-butyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamideamino)propanoic acid Ethyl ester

4-(1-(tert-butyl)benzylideneamino)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzoic acid 27c (362 mg, 0.68 mmol) , 3-aminopropionic acid ethyl ester hydrochloride (210 mg, 1.36 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate The ester (390 mg, 1.02 mmol) and N,N-diisopropylethylamine (0.50 mL, 2.72 mmol) were dissolved in 6 mL of N,N-dimethylformamide and the reaction was allowed to react at room temperature 4 hours. To the reaction mixture, 25 mL of water was added, and the mixture was combined with EtOAc (EtOAc (EtOAc) Purification by gel column chromatography (eluent: system C) to give 3-(4-(1-(tert-butyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl Ethylpentane-2-yl)benzhydrylamino)propanoate 27d (170 mg, white solid), yield: 39.9%.

MS m/z (ESI): 627.0 [M+1]

the fourth step

3-(4-(1-(tert-butyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzamideamino)propanoic acid

3-(4-(1-(tert-Butyl)benzylidinium)-1-(4-(trifluoromethoxy)phenyl)pentan-2-yl)benzylideneamino)propyl Ethyl acetate 27d (170 mg, 0.27 mmol) and 0.30 mL of lithium hydroxide monohydrate (60 mg, 1.40 mmol) were dissolved in a mixture of 8 mL of tetrahydrofuran and methanol (V/V = 3/1). The reaction was carried out at 25 ° C for 4 hours. The reaction mixture was concentrated under reduced pressure. EtOAc (EtOAc m. The residue is purified by silica gel column chromatography (eluent: system C) to give 3-(4-(1-(tert-butyl) benzhydryl)-1-(4-(trifluoromethoxy) Phenyl)pentan-2-yl)benzamide aminopropionic acid 27 (110 mg, white solid), yield: 68.3%.

MS m/z (ESI): 598.9 [M+1]

¹ H NMR (400 MHz, DMSO) δ 12.20 (s, 1H), 8.55 (d, J = 8.8 Hz, 1H), 8.45 (t, J = 5.3 Hz, 1H), 7.76 (d, J = 8.1 Hz, 2H), 7.70 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 8.1 Hz, 2H), 7.45 – 7.29 (m, 6H), 5.29 – 5.19 (m, 1H), 3.41 (dd, J = 12.8, 7.0 Hz, 2H) , 3.27 - 3.16 (m, 1H), 2.47 (d, J = 7.1 Hz, 2H), 1.52 (dd, J = 17.2, 5.5 Hz, 1H), 1.25 (s, 9H) , 1.07 (dd, J = 15.6, 8.9 Hz, 1H), 0.93 – 0.78 (m, 2H), 0.62 (t, J = 7.2 Hz, 3H).

Example 28

3-(4-((2R,3R)/(2S,3S)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4 -yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 28

3-(4-((2R,3R)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino)- 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propanoic acid 28A

3-(4-((2S,3S)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino)- 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propanoic acid 28B

first step

3-(4-((2R,3R)/(2S,3S)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4 -yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propionic acid ethyl ester

((2R,3R)/(2S,3S))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1s (82.0 g, 165.5 mmol), 3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-amine 4c (37.9 g, 165.5 mmol), bis(2-oxo-3-oxazolidinyl)phosphorus chloride (83.8 g, 329.8 mmol) was dissolved in 820 mL of dichloromethane, and N,N- was added with stirring. Diisopropylethylamine (145.7 mL, 827.7 mmol) was stirred at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted elution ((3-Fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethyl) Ethoxy)phenyl)hexane-3-yl)benzhydrylamino)propanoate 28a (110.0 g, white solid), yield: 94.0%.

MS m/z (ESI): 706.9 [M+1]

Second step

3-(4-((2R,3R)/(2S,3S)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4 -yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3R)/(2S,3S)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]- 4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propionic acid ethyl ester 28a (110.0 g, 155.6 Methyl) was dissolved in a mixed solvent of 1200 mL of tetrahydrofuran and methanol (V/V = 1:1), and added to a solution of 65 mL of lithium hydroxide monohydrate (65.0 g, 1.56 mol) under stirring, and stirred at room temperature for 2 hours. After adding 1000 mL of ethyl acetate, it was washed with 1 M of dilute hydrochloric acid (1500 mL), and then washed with saturated aqueous ammonium chloride (1000 mL). Purification by gel column chromatography (eluent: system A) gave 3-(4-((2R,3R)/(2S,3S)-1-((3-fluoro-2',4',6') -Trimethyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzene Formamidine)propionic acid 28 (82.0 g, white solid), yield: 77.7%.

MS m/z (ESI): 678.9 [M+1]

3-(4-((2R,3R)/(2S,3S)-1-((3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4 -yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propanoic acid 28 is further passed through a chiral column Supercritical fluid chromatography (SFC) method, using preparative equipment and chiral column chiral isomers for resolution ((1) Chiral Pak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and/or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (3) Whelk O1 (S, S ), 25 × 3 cm, 70 mL / min; mobile phase A for CO ₂ and B for Ethanol)) was resolved to obtain 3-(4-((2R,3R)-1-((3-fluoro-2') ,4',6'-Trimethyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane 3-yl)benzimidamide)propionic acid 28A and 3-(4-((2S,3S)-1-((3-fluoro-2',4',6'-trimethyl-[1 ,1'-Biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 28B.

28A: MS m/z (ESI): 678.9 [M+1]

¹ H NMR (400MHz, DMSO-d ₆ ) δ = 10.17 (s, 1 H), 8.44 - 8.32 (m, 1 H), 8.01 (t, J = 8.3 Hz, 1 H), 7.70 - 7.57 (m, 2 H), 7.42 (d, J = 8.5 Hz, 2 H), 7.24 - 7.10 (m, 4 H), 7.06 (d, J = 11.8 Hz, 1 H), 6.97 - 6.84 (m, 3 H), 4.40 (d, J = 11.3 Hz, 1 H), 3.56 - 3.33 (m, 4 H), 2.30 - 2.18 (m, 3 H), 2.03 - 1.85 (m, 6 H), 1.74 (d, J = 15.6 Hz, 2 H), 1.14 - 0.93 (m, 4 H), 0.88 - 0.72 (m, 3 H).

28B: MS m/z (ESI): 678.9 [M+1]

¹ H NMR (400 MHz , DMSO-d ₆ ) δ = 9.81 (s, 1 H), 8.08 - 7.96 (m, 1 H), 7.65 (t, J = 8.3 Hz, 1 H), 7.34 - 7.21 (m, 2 H), 7.06 (d, J = 8.5 Hz, 2 H), 6.88 – 6.74 (m, 4 H), 6.71 (d, J = 11.8 Hz, 1 H), 6.61 - 6.48 (m, 3 H), 4.04 (d, J = 11.3 Hz, 1 H), 3.20 – 2.97 (m, 4 H), 2.28 - 2.08 (m, 3 H), 2.01 - 1.80 (m, 6 H), 1.54 (d, J = 15.6 Hz, 2 H), 1.11 - 0.92 (m, 4 H), 0.87 - 0.72 (m, 3 H).

Example 29

3-(4-((2R,3R)/(2S,3S)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-) 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid 29

3-(4-((2R,3R)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2 -(4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propanoic acid 29A

3-(4-((2S,3S)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2 -(4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 29B

first step

3-(4-((2R,3R)/(2S,3S)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-) Ethyl 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamine)propionate

((2R,3R)/(2S,3S))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1s (80 mg, 0.16 mmol), 4'-chloro-2'-methyl-[1,1'-biphenyl]-4-amine 1n (52 mg, 0.24 Methyl), 1-hydroxybenzotriazole (43 mg, 0.32 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (61 mg, 0.32 mmol) dissolved in 20 N,N-diisopropylethylamine (0.14 mL, 0.8 mmol) was added to dichloromethane, and stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted eluted eluted eluted elution ((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl) Ethyl hexane-3-yl)benzylideneamino)propanoate 29a (58 mg, white solid), yield: 51.8%.

MS m/z (ESI): 695.8 [M+1]

Second step

3-(4-((2R,3R)/(2S,3S)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-) 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3R)/(2S,3S)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino) Ethyl-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoate 29a (58 mg, 0.083 mmol) dissolved in 6 mL A mixed solvent of tetrahydrofuran and methanol (V/V = 1:1) was added to a solution of 1 mL of sodium hydroxide (17 mg, 0.42 mmol) with stirring, and stirred at room temperature for 3 hours. The reaction mixture was concentrated with EtOAc EtOAc (EtOAc)EtOAc. Filtration and concentration under reduced pressure gave 3-(4-((2R,3R)/(2S,3S)-1-((4'-chloro-2'-methyl-[1,1'-biphenyl]] 4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzamide amino)propanoic acid 29 (40 mg, white solid ), yield: 71.0%.

MS m/z (ESI): 667.8 [M+1]

^{1 H NMR (400MHz, DMSO-} d 6) δ10.46 (s, 1 H), 8.37 (. Br s, 1 H.), 7.68 (s, 2 H), 7.65 - 7.60 (m, 2 H), 7.43 - 7.35 (m, 3 H), 7.28 (d, J = 8.0 Hz, 3 H), 7.18 (d, J = 8.0 Hz, 2 H), 7.13 (s, 3 H), 4.09 (d, J = 11.3 Hz, 1 H), 2.46 (br. s., 2 H), 2.22 (s, 3 H), 1.73 (br. s., 1 H), 1.31 - 1.15 (m, 2 H), 1.08 - 0.94 (m, 2 H), 0.88 - 0.72 (m, 2 H), 0.90 - 0.69 (m, 3 H).

3-(4-((2R,3R)/(2S,3S)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-) 1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzylideneamino)propanoic acid 29 was further prepared by supercritical fluid chromatography (SFC) Equipment and chiral column chiral isomers are resolved (1) chiral column ChiralPak AD, 25 × 3 cm, 80 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (2) Whelk O1 (S, S), 25 × 3 cm, 65 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL / min; The mobile phase A for CO ₂ and B for Ethanol)) was resolved to give 3-(4-((2R,3R)-1-((4'-chloro-2'-methyl-[1,1'-- Biphenyl]-4-yl)amino)-1-oxo-2-(4-(trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propanoic acid 29A and 3- (4-((2S,3S)-1-((4'-Chloro-2'-methyl-[1,1'-biphenyl]-4-yl)amino)-1-oxo-2-() 4-(Trifluoromethoxy)phenyl)hexane-3-yl)benzimidamide)propanoic acid 29B.

29A: MS m/z (ESI): 667.8 [M+1]

29B: MS m/z (ESI): 667.8 [M+1]

Example 30

3-(4-((2R,3R)/(2S,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6 '-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propionic acid 30

3-(4-((2R,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6'-trimethyl-) [1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propionic acid 30A

3-(4-((2S,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6'-trimethyl-) [1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propionic acid 30B

first step

3-(4-((2R,3R)/(2S,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6 '-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)ethyl propionate

((2R,3R)/(2S,3S))-3-(4-((3-ethoxy-3-oxopropyl)carbamoyl)phenyl)-2-(4-( Trifluoromethoxy)phenyl)hexanoic acid 1s (80 mg, 0.16 mmol), 2',4',6'-trimethyl-[1,1'-biphenyl]-4-amine 2a (63.4 mg , 0.3 mmol), 1-hydroxybenzotriazole (40.5 mg, 0.3 mmol) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (49.8 mg, 0.26 mmol) N,N-diisopropylethylamine (0.09 mL, 0.5 mmol) was added to 10 mL of dichloromethane and stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified eluted eluted eluted eluted eluted elut elut elut elut elut elut elut Oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl) Amino)hexane-3-yl)benzamide amino)propanoate 30a (50 mg, white solid), yield: 45.4%.

MS m/z (ESI): 690.0 [M+1]

Second step

3-(4-((2R,3R)/(2S,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6 '-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propionic acid

3-(4-((2R,3R)/(2S,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4', 6'-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzylideneamino)propionic acid ethyl ester 30a (50 mg, 0.072 mmol) 6 mL of a mixed solvent of tetrahydrofuran and methanol (V/V = 1:1) was added to a solution of 1 mL of sodium hydroxide (14.4 mg, 0.36 mmol) with stirring, and stirred at room temperature for 3 hours. The reaction mixture was concentrated with EtOAc (EtOAc)EtOAc. The residue was purified by thin layer chromatography (developing solvent: system A) to give 3-(4-((2R,3R)/(2S,3S)-1-oxo-2-(4-(trifluoro) Oxy)phenyl)-1-((2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidazole Amino)propionic acid 30 (17 mg, white solid), yield: 29.4%.

MS m/z (ESI): 661.9 [M+1]

¹ H NMR (400 MHz, DMSO) δ 10.42 (s, 1H), 8.37 (s, 1H), 7.68 (d, J = 8.1 Hz, 2H), 7.63 (d, J = 7.5 Hz, 2H), 7.40 ( d, J = 8.6 Hz, 2H), 7.18 (d, J = 7.9 Hz, 2H), 7.13 (d, J = 8.3 Hz, 2H), 7.04 (d, J = 8.3 Hz, 2H), 6.90 (s, 2H), 4.10 (d, J = 11.1 Hz, 1H), 3.63 (t, J = 6.9 Hz, 2H), 3.51 – 3.43 (m, 1H), 2.47 (s, 3H), 2.25 (s, 3H), 1.92 (s, 6H), 1.80 – 1.68 (m, 2H), 1.06 – 0.97 (m, 2H), 0.79 (t, J = 7.2 Hz, 3H).

3-(4-((2R,3R)/(2S,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6 '-Trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzhydrylamino)propanoic acid 30 is further subjected to supercritical fluid chromatography (SFC), Resolution by preparative equipment and chiral column chiral isomers ((1) chiral column ChiralPak AD, 25×3 cm, 80 mL/min; mobile phase A for CO ₂ and B for Ethanol; and/or (2 Whelk O1 (S, S), 25 × 3 cm, 65 mL / min; mobile phase A for CO ₂ and B for Ethanol; and / or (3) Whelk O1 (S, S), 25 × 3 cm, 70 mL / Min; mobile phase A for CO ₂ and B for Ethanol)) was resolved to give 3-(4-((2R,3R)-1-oxo-2-(4-(trifluoromethoxy)phenyl) )-1-((2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzylideneamine)propionic acid 30A and 3-(4-((2S,3S)-1-oxo-2-(4-(trifluoromethoxy)phenyl)-1-((2',4',6'-trimethyl) Base-[1,1'-biphenyl]-4-yl)amino)hexane-3-yl)benzimidamide)propanoic acid 30B.

30A: MS m/z (ESI): 661.9 [M+1]

30B: MS m/z (ESI): 661.9 [M+1]

Example 31

3-(4-(1-(3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)-1-(4- (trifluoromethoxy)phenyl)-pentan-2-yl)benzamide amino)propionic acid

3-(4-((1R,2R)-1-(3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido) 1-(4-(trifluoromethoxy)phenyl)-pentan-2-yl)benzamide amino)propanoic acid 31A

3-(4-((1S,2S)-1-(3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido) 1-(4-(trifluoromethoxy)phenyl)-pentan-2-yl)benzimidamide)propionic acid 31B

first step

4-(1-(3-Fluoro 2',4,6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)-1-(4-(trifluoromethoxy) Tert-butyl phenyl)-pentan-2-yl)benzoate

4-(1-Amino-1-(4-(trifluoromethoxyphenyl)pentan-2-yl)benzoic acid tert-butyl ester 11b (5.50 g, 13.0 mmol), 3-fluoro-2', 4',6'-trimethyl-[1,1'-biphenyl]-4-carboxylic acid 31a (3.95 g, 15.3 mmol), bis(2-oxo-3-oxazolidinyl)phosphinium Chlorine (6.00 g, 23.6 mmol) and N,N-diisopropylethylamine (8.2 mL, 47.2 mmol) were dissolved in 60 mL dichloromethane and N,N-dimethylformamide (V/V=5 In the mixed solvent of /1), the reaction liquid was reacted at 30 ° C for 18 hours. The reaction liquid was concentrated under reduced pressure, then 50 mL water was added, and extracted with ethyl acetate (25 mL×3), and the organic phase was combined with water (50 mL×3) Washed, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (eluent: System A) to give 4-(1-(3-fluoro 2', 4, 6'-Trimethyl-[1,1'-biphenyl]-4-ylcarbamido)-1-(4-(trifluoromethoxy)phenyl)-pentan-2-yl)benzene Tert-butyl formate 31b (7.13 g, pale yellow solid), yield: 82.8%.

MS m/z (ESI): 607.9 [M+1-56]

Second step

4-(1-(3-Fluoro-2',4,6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)-1-(4-(trifluoromethyl) Oxy)phenyl)-pentan-2-yl)benzoic acid

4-(1-(3-Fluoro 2',4,6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)-1-(4-(trifluoromethyl) tert-Butyl oxy)phenyl)-pentan-2-yl)benzoate 31b (7.13 g, 10.7 mmol) and 85% phosphoric acid (4.5 mL, 66.0 mmol) were dissolved in 50 mL of acetonitrile. The reaction was carried out at ° C for 4 hours. After the reaction mixture was concentrated, EtOAc (EtOAc m.) 4,6'-trimethyl-[1,1'-biphenyl]-4-ylcarbamido)-1-(4-(trifluoromethoxy)phenyl)-pentan-2-yl Benzoic acid 31c (6.50 g, yellow solid), yield: 100%.

MS m/z (ESI): 607.9 [M+1]

third step

3-(4-(1-(3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)-1-(4- (trifluoromethoxy)phenyl)-pentan-2-yl)benzamide amino)propionic acid ethyl ester

4-(1-(3-Fluoro-2',4,6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)-1-(4-(trifluoro) Methoxy)phenyl)-pentan-2-yl)benzoic acid 31c (6.50 g, 10.7 mmol), 3-aminopropionic acid tert-butyl ester hydrochloride (3.90 g, 21.4 mmol), 2-(7- Azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (6.10 g, 16.1 mmol) and N,N-diisopropylethylamine (7.50 mL, 42.8 Methyl) was dissolved in 60 mL of di-N,N-dimethylformamide, and the reaction was allowed to react at 25 ° C for 3 hours. 250 mL of water was added to the reaction mixture, and the mixture was extracted with EtOAc (EtOAc (EtOAc) Purification by silica gel column chromatography (eluent: dichloromethane: methanol) gave 3-(4-(1-(3-fluoro-2',4',6'-trimethyl-[1 ,1'-biphenyl]-4-ylcarbamimidyl)-1-(4-(trifluoromethoxy)phenyl)-pentan-2-yl)benzylideneamino)propionic acid ethyl ester 31d (7.86 g, yellow solid), yield: 100%.

MS m/z (ESI): 678.9 [M+1-56]

the fourth step

3-(4-(1-(3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)-1-(4- (trifluoromethoxy)phenyl)-pentan-2-yl)benzamide amino)propionic acid

3-(4-(1-(3-Fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)-1-(4) -(Trifluoromethoxy)phenyl)-pentan-2-yl)benzimidamide ethyl propionate 31d (7.86 g, 10.7 mmol) and 85% phosphoric acid (4.5 mL, 64.2 mmol) The reaction solution was reacted at 80 ° C for 4 hours in 100 mL of acetonitrile. The reaction mixture was concentrated with EtOAc EtOAc EtOAc EtOAc. 3-(4-(1-(3-Fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)-1-(4) -(Trifluoromethoxy)phenyl)-pentan-2-yl)benzhydrylamino)propanoic acid 31 (7.10 g, pale yellow solid), yield: 97.8%.

MS m/z (ESI): 678.9 [M+1]

¹ H NMR (400 MHz, CDCl ₃ ) δ 7.98 (t, J = 7.8 Hz, 1H), 7.72 (d, J = 6.7 Hz, 2H), 7.27 (d, J = 5.0 Hz, 2H), 7.21 (d , J = 6.2 Hz, 2H), 7.17 (d, J = 7.9 Hz, 2H), 7.13-7.04 (m, 1H), 6.98 (d, J = 7.7 Hz, 1H), 6.91 (d, J = 3.2 Hz , 2H), 6.87 (d, J = 12.7 Hz, 2H), 5.48 (t, J = 6.2 Hz, 1H), 3.73 (q, J = 7.0 Hz, 2H), 3.10 (s, 1H), 2.31 (s , 3H), 1.98 (s, 3H), 1.92 (s, 3H), 1.66 (ddd, J = 30.3, 11.0, 4.5 Hz, 2H), 1.24 (t, J = 7.0 Hz, 2H), 1.14 (dd, J = 14.4, 7.1 Hz, 2H), 0.79 (t, J = 7.1 Hz, 3H).

3-(4-(1-(3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-ylcarboxamido)-1-(4- (Trifluoromethoxy)phenyl)-pentan-2-yl)benzylideneamine)propionic acid 31 further by using supercritical fluid chromatography (SFC), using preparative equipment and chiral columns for heterogeneous heterogeneity Resolution of the body (chiral column Whelk O1 (S, S), 250 × 4.6 mm ID, mobile phase A for CO ₂ and B for Ethanol; A for CO ₂ and B (50%) for Methanol (0.05% DEA) Resolution is carried out to give 3-(4-((1R,2R)-1-(3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4- Benzylamino)-1-(4-(trifluoromethoxy)phenyl)-pentan-2-yl)benzylidene amino)propionic acid 31A (retention time: 4.95 min; ee value: 100 %) and 3-(4-((1S,2S)-1-(3-fluoro-2',4',6'-trimethyl-[1,1'-biphenyl]-4-ylformamidine Amino)-1-(4-(trifluoromethoxy)phenyl)-pentan-2-yl)benzylideneamino)propanoic acid 31B (retention time: 11.28 min; ee: 100%).

31A: MS m/z (ESI): 678.9 [M+1]

¹ H NMR (400 MHz, DMSO) δ 12.19 (s, 1H), 8.69 (d, J = 8.6 Hz, 1H), 8.49 (t, J = 5.2 Hz, 1H), 7.82 (d, J = 8.1 Hz, 2H), 7.69 (d, J = 8.5 Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 7.13 (t, J = 7.7 Hz, 1H) , 6.96 (d, J = 10.9 Hz, 1H), 6.89 (m, 3H), 5.31 (t, J = 9.7 Hz, 1H), 3.45 (dd, J = 12.4, 6.7 Hz, 2H), 3.17 (t, J = 9.3 Hz, 1H), 2.52 (d, J = 7.1 Hz, 3H), 2.24 (s, 3H), 1.88 (d, J = 2.0 Hz, 7H), 1.54 (d, J = 10.1 Hz, 1H) , 1.12 (d, J = 6.9 Hz, 1H), 0.86 (m, 2H), 0.63 (t, J = 7.2 Hz, 3H).

31B: MS m/z (ESI): 678.9 [M+1]

¹ H NMR (400 MHz, DMSO) δ 12.21 (s, 1H), 8.68 (d, J = 8.7 Hz, 1H), 8.49 (t, J = 5.3 Hz, 1H), 7.82 (d, J = 8.1 Hz, 2H), 7.69 (d, J = 8.5 Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 7.13 (t, J = 7.7 Hz, 1H) , 6.96 (d, J = 10.9 Hz, 1H), 6.89 (m, 3H), 5.31 (t, J = 9.7 Hz, 1H), 3.45 (dd, J = 12.6 Hz, 6.8 Hz, 2H), 3.17 (dd , J = 10.9 Hz, 7.8 Hz, 1H), 2.51 (s, 2H), 2.24 (s, 3H), 1.88 (d, J = 2.3 Hz, 6H), 1.54 (d, J = 10.6 Hz, 1H), 1.12 (d, J = 7.2 Hz, 1H), 0.88 (m, 2H), 0.63 (t, J = 7.2 Hz, 3H).

Biological evaluation

Test Example 1. Inhibition of glucagon-induced intracellular cAMP production by the compounds of the present invention

The method uses a HEK293 cell line with high expression of human glucomannin receptor (hGCGR) (purchased from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) as a test model to test the test compound at the cellular level to the glycemic receptor. Antagonism. HEK293-hGCGR cells were supplemented with 10% fetal bovine serum (FBS, GIBCO Cat. No. 10099141) in F12 medium (Invitrogen Cat #11765047) and cultured at 37 ° C, 5% CO ₂ . At the time of the experiment, cells were seeded at 3,000 cells/well in 384-well cell culture plates (OptiPlate-384, white, PerkinElmer Cat. No. 6007290). Compounds were first dissolved in DMSO and then serially diluted to the desired concentration. Each compound was set at 10 concentrations of 50 μM, 16.7 μM, 5.56 μM, 1.85 μM, 0.62 μM, 0.21 μM, 69 nM, 23 nM. , 7.5 nM and 2.5 nM. After the cells were administered with the cells, the cells were stimulated with glycoside (Sigma, 0.05 nM) and incubated for 1 hour at room temperature. Subsequently, the test solution was added by Lance cAMP384 Kit (PerkinElmer, Cat. #AD0263), and the incubation was continued for 1 hour at room temperature and the intracellular cyclic adenosine monophosphate (cAMP) level was determined according to the kit instructions. The degree of inhibition of cAMP production by the test compound at each concentration was determined by comparison with the cAMP level of the blank control cells, and then the dose-effect relationship curve of the compound logarithmic concentration (the logarithm of the compound concentration)-inhibition level (inhibition rate) was plotted. And performing nonlinear regression analysis to calculate the IC ₅₀ value of the compound. A similar method is suitable for testing cell lines that highly express the human ghlylin-like peptide 1 receptor (hGLP-1R) and the gastrin inhibitor peptide receptor (GIPR) to determine the selectivity of the compound for GCGR.

The IC ₅₀ values of preferred compounds of the invention for inhibition of GCGR are shown in Table 1.

Table 1 IC ₅₀ values of preferred compounds of the invention for inhibition of GCGR

Conclusion: The preferred compounds of the invention have a significant inhibitory effect on GCGR.

Test Example 2, Pharmacokinetic Test of Compound 4A and Compound 4B of the Present Invention

Summary

SD rats were used as test animals, and the compounds in compound 4A and compound 4B were intragastrically administered by LC/MS/MS method. The drug concentrations in plasma were measured at different times. The compounds of the present invention were studied in rats. Generation dynamics.

Experimental program

2.1 Experimental drugs and animals

Compound 4A and Compound 4B; 6 healthy adult SD male rats, purchased from Vitallihua Laboratory Animal Technology Co., Ltd., production license number: 11400700109943.

2.2 Drug configuration and drug delivery

Weigh 3mg of the experimental drug, add 1mL of ethanol, ultrasonically to the solution, add 1.5mL PEG400 and 2.5mL water, while vortex mixing, configured to 0.6 mg / mL;

Six healthy adult SD male rats were intragastrically administered overnight after fasting, and the dose was 3 mg/kg.

2.3 Sample Collection

0.15 mL of laryngeal venous blood was taken before administration and 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 24 hours after administration, and placed in heparinized tubes at 5500 rpm. Centrifuge for 10 minutes, store at -30 ° C, and eat 4 hours after administration.

2.4 Sample Processing

For plasma samples:

Take 20 μL of the sample, add IS (containing verapamil 5 ng·mL-1 and glibenclamide 50 ng·mL-1) in 100 μL acetonitrile, vortex for 0.2 minutes, 13000 rpm After 8 minutes, 70 μL of the supernatant was added to 70 μL of water, vortexed for 10 minutes, and the supernatant of 10 μL of the mixture was taken to an LC-MS/MS system for analysis.

For dose sample:

The administered sample was diluted with a mixed solvent of methanol and water (1:1, v/v) to a concentration of 100 ng·mL-1, and 100 μL of the diluted sample and 100 μL of the internal standard solution (100 ng·mL- 1) Add 500 μL of IS solution and 600 μL of water, then vortex to mix, and take 10 μL of the supernatant to the LC-MS/MS system for analysis.

3, pharmacokinetic parameters results

The pharmacokinetic parameters of the preferred compounds of the invention are shown in Table 2.

Table 2 Pharmacokinetic data sheets for Compound 4A and Compound 4B

Conclusion: Preferred compounds 4A and 4B of the present invention have better pharmacokinetic properties.

Test Example 3: Effect of single oral administration of the compound of the present invention on random blood glucose in db/db mice

Purpose

Observing the effect of the preferred compound of the present invention on the random blood glucose of the type 2 diabetes model db/db mice after a single oral administration, using the tail blood sampling method, the blood glucose level is measured by the portable blood glucose meter, and then the test is performed on the blood glucose meter. The in vivo hypoglycemic effect of the compounds was evaluated.

Test animal

Forty-two male db/db mice, 9-10 weeks, were provided by the Institute of Model Animals of Nanjing University, license number: SCXK (Su) 2010-0001, and a positive control group and a solvent control group were set.

Test substance

Compounds 4, 4A, 5, 19, 23, 25 and 28A, 3-(4-((1R,2S)-1-(5-chloro-7-fluoro-1H-indol-3-yl) disclosed in WO20150662521 -1 -(4-(Trifluoromethoxy)phenyl)pentan-2-yl)benzylidinium)propionic acid (FORM1), prepared with ethanol: PEG400: water = 20:30:50 concentration.

Mode of administration

Oral gavage administration, the blank control group was given the same volume of ethanol: PEG400: water = 20:30:50, the administration volume was 10 ml/kg, and the administration dose was 30 mg/kg.

experiment method

Male db/db mice were divided into groups according to non-fasting blood glucose and body weight, and each group consisted of a solvent control and a drug administration group of different compounds. Each group of animals was given a single oral administration of the test drug and solvent, and the tail blood glucose level was measured before and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h and 24 h after the administration, and the hypoglycemic effect of the test substance was observed. Maintain time and draw a 24-hour blood glucose curve. The modulation of blood glucose by the compounds was determined by comparison to the blood glucose of db/db mice administered only vehicle control.

Experimental result

The blood glucose lowering rate of the preferred compounds of the present invention is shown in Table 3.

Table 3 Table of blood glucose lowering rates of preferred compounds of the invention

Conclusion: The preferred compounds of the invention show better hypoglycemic effects at 4 and 6 hours.

Test Example 4: Effect of Oral Administration of Preferred Compounds of the Invention on Random Blood Glucose in db/db Mice for 28 Days Oral Administration

Purpose

To observe the effect of the preferred compound of the present invention on the random blood glucose of the type 2 diabetes model db/db mice after oral administration for 28 consecutive days, and adopt the tail blood sampling method to measure the blood glucose level by the portable blood glucose meter, and then test the blood glucose level. The in vivo hypoglycemic effect of the compounds was evaluated.

Test animal

100 male db/db mice, 9-10 weeks, were provided by the Institute of Model Animals, Nanjing University, license number: SCXK (Su) 2010-0001, and a positive control group and a solvent control group were set.

Test substance

Compound 4A, 28A, sitagliptin (a marketed drug), 3-(4-((1R,2S)-1-(5-chloro-7-fluoro-1H-indol-3-yl) disclosed in WO20150662521 -1 -(4-(Trifluoromethoxy)phenyl)pentan-2-yl)benzylidinium)propionic acid (FORM1), prepared with ethanol: PEG400: water = 20:30:50 concentration.

Mode of administration

Oral gavage administration, the blank control group was given the same volume of ethanol: PEG400: water = 20:30:50, the administration volume was 10 ml/kg, and the administration dose was 30 mg/kg.

experiment method

Male db/db mice were divided into groups according to non-fasting blood glucose and body weight, and each group consisted of a solvent control and a drug administration group of different compounds. Each group of animals was orally administered with the test drug and solvent for 28 consecutive days, and the tail blood glucose level was detected on the first day, the seventh day, the 14th day, the 21st day, and the 28th day after the administration, and the test article was observed. Reduce blood sugar and maintain time, and draw a 28-day blood glucose curve. The modulation of blood glucose by the compounds was determined by comparison to the blood glucose of db/db mice administered only vehicle control.

Experimental result

The db/db mice were orally administered with the preferred compound 4A of the present invention, the compound 28B, and the compound (FORM1) of sitagliptin and WO2015066252 for 28 consecutive days. In contrast, the compound 4A and the compound 28B have significant hypoglycemic effect. Desistatin and FORM1 are shown in Figure 1.

All documents mentioned in the present application are hereby incorporated by reference in their entirety in their entireties in the the the the the the the the In addition, it is to be understood that various modifications and changes may be made to the inventions of the present invention.

no

Fig. 1 is a graph showing changes in blood glucose levels of a compound of the present invention for db/db mice for 28 days, wherein the ordinate is the blood glucose level (mmol/L) and the abscissa is the administration time (days).

Claims (36)

A compound of the formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof: Wherein: L is selected from -C(O)NH- or -NH-C(O)-; A ₁ , A ₂ , A ₃ , A ₄ and A ₅ are each independently selected from CH, C or N, provided that A ₁ a ring of A ₂ , A ₃ , A ₄ and A ₅ and a carbon atom to which they are bonded, wherein the number of N is 0 to 2; R ^{1 is} selected from an alkyl group or a cycloalkyl group, wherein the alkane is The base or cycloalkyl group is further optionally further selected from one or more selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁶ R ⁷ Substituted by a substituent of -C(O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ ; R ² Selected from hydrogen atom, alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, cyano, nitro, cycloalkyl, heterocyclic, aryl, heteroaryl, -NR ⁶ R ⁷ , - C(O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ , wherein the alkyl group, the alkenyl group Or alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further further selected from one or more selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, Haloalkyl, haloalkoxy, cycloalkyl, heterocyclic Base, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ Substituted by a substituent of C(O)R ⁷ ; when A _{3 is} selected from N, R ² is absent; R ^{3 is} each independently selected from a hydrogen atom, an alkyl group, a halogen, a hydroxyl group, an alkoxy group, a cyano group, a nitrate Base, cycloalkyl, heterocyclic, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C( O) OR ⁸ or -NR ⁶ C(O)R ⁷ , wherein said alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl group is further selectively selected by one or more From hydroxy, halogen, nitro, cyano, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ Substituents of R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ are substituted; R ^{4 is} each independently selected from a hydrogen atom, Alkyl, halogen, hydroxy, alkoxy, cyano, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C (O) R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ , wherein the alkyl group, the alkoxy group, The cycloalkyl, heterocyclyl, aryl or heteroaryl group is further optionally further selected from one or more selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, Heterocyclyl, aryl, heteroaryl, -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or - Substituted by a substituent of NR ⁶ C(O)R ⁷ ; R ⁵ are each independently selected from a hydrogen atom, an alkyl group, a halogen, a hydroxyl group, an alkoxy group, a cyano group, a nitro group, -NR ⁶ R ⁷ , -C ( O) NR ⁶ R ⁷ , -C(O)R ⁸ , -SO ₂ R ⁸ , -C(O)OR ⁸ or -NR ⁶ C(O)R ⁷ , wherein said alkyl or alkoxy group is selected Further further one or more selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁶ R ^{7, -C (O) NR 6} R 7, -C (O) R 8, -SO 2 R 8, -C (O) oR 8 or -NR ⁶ C (O) R ⁷ of the substituents; R & lt ^{6 is} selected from a hydrogen atom or an alkyl group; R ^{7 is} selected from a hydrogen atom, an alkyl group, a cycloalkyl group, an aryl group or a heteroaryl group, wherein the alkyl group, cycloalkyl group, aryl group or heteroaryl group is selectively selected Further selected from one or more selected from hydroxy Base, halogen, haloalkyl, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁹ R ¹⁰ , -C(O)R ⁹ R ¹⁰ Substituted by a substituent of -C(O)R ¹¹ , -SO ₂ R ¹¹ , -C(O)OR ¹¹ or -NR ⁹ C(O)R ¹⁰ ; alternatively, R ⁶ and R ⁷ are bonded to the N The atoms together form a 4-8 membered heterocyclic group wherein the heterocyclic group contains one or more N, O, S(O)q atoms, and the heterocyclic group is selectively further subjected to one or more Selected from alkyl, halogen, hydroxy, cyano, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl, -NR ⁹ R ¹⁰ , -C(O)R ⁹ R ¹⁰ , -C( O) R ¹¹ , -SO ₂ R ¹¹ , -C(O)OR ¹¹ or -NR ⁹ C(O)R ¹⁰ substituted; R ^{8 is} selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic ring Or an aryl or heteroaryl group, wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally selected from one or more selected from the group consisting of hydroxyl, halogen, haloalkyl, nitro, cyanide Base, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, -NR ⁹ R ¹⁰ , -C(O)R ⁹ R ¹⁰ , -C(O)R ¹¹ , -SO ₂ R ¹¹ , -C(O)OR ¹¹ or -NR ⁹ Substituted by a substituent of C(O)R ¹⁰ ; R ⁹ , R ¹⁰ and R ¹¹ are each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkane a group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, optionally selected from one or more selected from the group consisting of a hydroxyl group, a halogen, a halogenated alkyl group, a nitro group, a cyano group, an alkyl group, an alkoxy group, a cycloalkyl group, Substituted by a substituent of a heterocyclic group, an aryl group, a heteroaryl group, a carboxylic acid or a carboxylic acid ester; m is 0, 1, 2, 3, 4 or 5; n is 0, 1, 2, 3 or 4; Is 0, 1, 2, 3 or 4; and q is 0, 1 or 2. The compound of the above formula, or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, which is a compound of the formula (II) or a stereoisomer thereof or a tautomer thereof. A conformation or a pharmaceutically acceptable salt thereof: Wherein, R ¹ to R ⁵ , m, n and p are as defined in the first item of the patent application. The compound of the above formula, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound of the formula (III) or a stereoisomer thereof or a tautomer thereof. A conformation or a pharmaceutically acceptable salt thereof: Wherein, R ¹ to R ⁵ , m, n and p are as defined in the first item of the patent application. A compound according to claim 2, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is of the formula (IV) or (V) or (VI) or (VII) a compound or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof: Wherein, R ¹ to R ⁵ , m, n and p are as defined in the first item of the patent application. A compound according to claim 3, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is of the formula (VIII) or (IX) or (X) or (XI) a compound or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof: Wherein, R ¹ to R ⁵ , m, n and p are as defined in the first item of the patent application. The compound of any one of claims 1 to 5, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ^{1 is} selected from C ₃ - ₆ alkyl, preferably The ground is n-propyl. The compound of any one of claims 1 to 5, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ^{2 is} selected from phenyl, wherein said phenyl group Optionally further substituted with one or more substituents of an alkyl, halogen, cyano, nitro, alkoxy, haloalkyl or haloalkoxy group, further preferred wherein the phenyl group is further subjected to one or more Substituted by methyl, trifluoromethyl or trifluoromethoxy. The compound of any one of claims 1 to 5, wherein the R ^{2 is} selected from a 5- to 8-membered heteroaryl group, or a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein R ^{2 is} selected from the group consisting of 5 to 8 membered heteroaryl. Said heteroaryl group is optionally further substituted by one or more substituents of an alkyl group, a halogen, a cyano group, a nitro group, an alkoxy group, a halogenated alkyl group or a halogenated alkoxy group, wherein R ^{2 is} further preferably pyrrole. , furan, thiophene, pyrazole, imidazole, thiazole, benzimidazole, benzofuran, or benzoxazole, wherein the pyrrole, furan, thiophene, pyrazole, imidazole, thiazole, benzimidazole, benzofuran, or The benzoxazole is optionally further substituted with one or more substituents of an alkyl, halogen, cyano, nitro or alkoxy group, wherein the alkyl or alkoxy group is further selectively one or more Substituted by a halogen substituent, the halogen is preferably F. The compound of any one of claims 1 to 5, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ^{3 is} selected from alkoxy, wherein said alkane The oxy group is optionally further substituted by one or more substituents selected from the group consisting of an alkyl group, a halogen, a cyano group, a nitro group or an alkoxy group, and R ^{3 is} preferably a fluoroalkoxy group, more preferably three Fluoromethoxy or trifluoroethoxy. The compound of claim 9 or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ^{3 is} attached to the 3 position (meta) or 4 (para), m It is preferably 1. The compound of any one of claims 1 to 5, wherein the R ^{4 is} selected from a hydrogen atom, a halogen or an alkyl group, or a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof. Preferably, F, n is preferably 1. The compound of claim 1, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein: A _{3 is} selected from C; R ^{1 is} selected from n-propyl; R ^{2 is} selected from Alkyl, halogen, cyano, nitro, alkoxy, haloalkyl, haloalkoxy, phenyl or 5- to 8-membered heteroaryl, alkyl, alkoxy, phenyl or 5-8 The heteroaryl group is optionally further substituted with one or more substituents of an alkyl group, a halogen, a cyano group, a nitro group, an alkoxy group, a halogenated alkyl group or a halogenated alkoxy group; R ^{3 is} selected from the group consisting of trifluoromethoxy; ^{4 is} selected from a hydrogen atom or a halogen; R ^{5 is} each independently selected from a hydrogen atom, an alkyl group, a halogen, an alkoxy group, a halogenated alkyl group or a halogenated alkoxy group; m is 0, 1 or 2; n is 0, 1 or 2; And p is 0, 1, or 2. The compound of claim 1, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein the compound comprises: or . The compound of claim 1, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein the compound comprises: or . The compound of claim 14, or a stereoisomer, tautomer, racemate thereof or a pharmaceutically acceptable salt thereof, wherein the compound comprises: or . The compound of claim 1, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein the compound comprises: or . The compound of claim 16 or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein the compound comprises: or . A method for preparing a compound of formula (I) according to claim 1 of the scope of the patent application, the method comprising: The compound of the formula (IA) is reacted with the formula (IB), and the obtained compound is further hydrolyzed to obtain a compound of the formula (I): wherein: L _{1 is} selected from -C(O)X; L _{2 is} selected from -NH ₂ ; From a hydroxyl group or a halogen; Rc is selected from an alkyl group; L is selected from -NH-C(O)-; and R ¹ to R ⁵ , A ₁ to A ₅ , m, n and p are as defined in claim 1 Said in the middle. The preparation method according to claim 18, wherein the preparation method of the general formula (IA) comprises: The general formula (IC) and the general formula (ID) or a salt thereof are reacted to obtain a compound of the formula (IA): wherein: L _{1 is} selected from -C(O)X; X is selected from a hydroxyl group or a halogen; and R ^{c is} selected from an alkyl group. And R ¹ , R ³ , R ⁴ , m, n are as defined in the first item of the patent application. A method for preparing a compound of formula (I) according to claim 1 of the scope of the patent application, the method comprising: The compound of the formula (IE) is reacted with the formula (ID) or a salt thereof, and the obtained compound is further hydrolyzed to obtain a compound of the formula (I): wherein: X is selected from a hydroxyl group or a halogen; R ^{c is} selected from an alkyl group; C(O)-NH-; and R ¹ to R ⁵ , A ₁ to A ₅ , m, n and p are as defined in Patent Application No. 1. The preparation method according to claim 20, wherein the preparation method of the general formula (IE) comprises: The general formula (IC) and the general formula (IB) or a salt thereof are reacted to obtain a compound of the general formula (IE); wherein: L _{1 is} selected from -NH ₂ ; L _{2 is} selected from -C(O)X; and X is selected from a hydroxyl group. Or halogen; L is selected from -C(O)-NH-; and R ¹ to R ⁵ , A ₁ to A ₅ , m, n and p are as defined in the first item of the patent application. A compound of the formula (IA): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof: Wherein: L _{1 is} selected from -C(O)X; X is selected from a hydroxyl group or a halogen; R ^{c is} selected from an alkyl group; and R ¹ , R ³ , R ⁴ , m and n are as defined in the first item of the patent application. Said. The compound of claim 22, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, comprising: . The compound of claim 22, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein the compound comprises: or . A compound of the formula (IE) or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof: Wherein: X is selected from a hydroxyl group or a halogen; L is selected from -C(O)-NH-; and R ¹ to R ⁵ , A ₁ to A ₅ , m, n and p are as defined in the first item of the patent application. Said. The compound of claim 25, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein the compound comprises: . A process for the preparation of a compound of formula (IA) according to claim 22, wherein the compound of formula (IA) is a compound of formula (IIA): , the method includes: The compound of the formula (IIa) is reacted with the compound of the formula (IIb) under basic conditions to give the formula (IIc); The compound of the formula (IIc) is hydrolyzed under basic conditions to give a compound of the formula (IId); The compound of the formula (IId) is reacted with the compound of the formula (IIe) in the presence of a condensation reagent to give a compound of the formula (IIf); Hydrolysis of the compound of the formula (IIf) under basic conditions gives the compound of the formula (IIA); wherein: X is selected from a hydroxyl group or a halogen; R ^a , R ^b and R ^c are each independently selected from an alkyl group; R ¹ , R ³ , R ⁴ , m and n are as defined in the first item of the patent application. The preparation method of claim 27, wherein the condensation reagent is selected from the group consisting of bis(2-oxo-3-oxazolidinyl)phosphorus chloride, N,N-dicyclohexylcarbodiimide. Amine, N,N-diisopropylcarbodiimide, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and o-benzotriazole-N,N,N 'N'-tetramethyluronium borate (TBTU); preferably 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride or bis(2-oxo-3) - oxazolidinyl)phosphorus chloride. The preparation method of claim 27, wherein the basic condition is provided by an organic base or an inorganic base selected from the group consisting of diisopropylethylamine, pyridine, triethylamine, acridine, N-methylpyridazine, 4-dimethylaminopyridine and potassium t-butoxide, preferably diisopropylethylamine, triethylamine or potassium t-butoxide; and the inorganic base is selected from the group consisting of sodium carbonate, carbonic acid Potassium, cesium carbonate, sodium hydride, sodium hydroxide, potassium hydroxide, lithium hydroxide and potassium hydride are preferably sodium hydroxide or lithium hydroxide. A process for the preparation of a compound of the formula (IE) according to claim 25, wherein the compound of the formula (IE) is a compound of the formula (IIIA): , the method includes: The compound of the formula (IIIa) is reacted in the presence of tetraisopropyl titanate and ammonia methanol to obtain the formula (IIIb); The condensation reaction of the compound of the formula (IIIb) with the formula (IIIc) gives the compound of the formula (IIId); The compound of the formula (IIId) is subjected to a hydrolysis reaction under acidic conditions to obtain a compound of the formula (IIIA): wherein: R ^a , R ^b and R ^{c are} selected from an alkyl group; and R ¹ to R ⁵ , m, n and p The definition is as described in item 1 of the patent application. The production method according to claim 30, wherein the acidic condition is provided by an inorganic acid or an organic acid selected from hydrochloric acid or phosphoric acid. A pharmaceutical composition, which comprises an effective amount of a compound according to any one of claims 1 to 17 or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. And a pharmaceutically acceptable carrier, excipient or a combination thereof. A method for inhibiting a glycoside receptor in vitro, which comprises intermingling the glycoside receptor with a compound according to any one of claims 1 to 17 or a stereoisomer thereof thereof. The construct or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 32 of the patent application is contacted. A compound according to any one of claims 1 to 17 or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical combination according to claim 32 Use of the drug in the preparation of a drug for type I diabetes, type II diabetes, hyperglycemia, obesity or insulin resistance. A compound according to any one of claims 1 to 17 or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical combination according to claim 32 Use of a substance in the preparation of a glycoside receptor antagonist or inverse agonist. A compound according to any one of claims 1 to 17 or a stereoisomer, tautomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical combination according to claim 32 The use of the medicament for the preparation of a medicament for treating hyperlipidemia, dyslipidemia, hypercholesterolemia, atherosclerosis, metabolic syndrome.